**QUEEN'S
UNIVERSITY
BELFAST**

Rapid ex vivo molecular fingerprinting of biofluids using laser-assisted rapid evaporative ionization mass spectrometry

Plekhova, V., Van Meulebroek, L., De Graeve, M., Perdonés-Montero, A., De Spiegeleer, M., De Paepe, E., Van de Walle, E., Takats, Z., Cameron, S. J. S., & Vanhaecke, L. (2021). Rapid ex vivo molecular fingerprinting of biofluids using laser-assisted rapid evaporative ionization mass spectrometry. *Nature Protocols*.
<https://doi.org/10.1038/s41596-021-00580-8>

Published in:
Nature Protocols

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights
Copyright 2021, the Authors.
This work is made available online in accordance with the publisher's policies. Please refer to any applicable terms of use of the publisher.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

83 **Rapid *ex vivo* molecular fingerprinting of biofluids using laser assisted rapid evaporative**
84 **ionization mass spectrometry**

85

86 Vera Plekhova^{1*}, Lieven Van Meulebroek^{1,2*}, Marilyn De Graeve¹, Alvaro Perdones-
87 Montero³, Margot De Spiegeleer¹, Ellen De Paepe¹, Emma Vande Walle¹, Zoltan Takats³,
88 Simon J.S. Cameron^{4#} & Lynn Vanhaecke^{1,4#}

89

90 * Equal first author contributions

91 # Equal last author contributions

92

93 ¹ Laboratory of Chemical Analysis, Ghent University, 9820 Merelbeke, Belgium.

94 ² ProDigest BV, Technologiepark-Zwijnaarde 82, 9052 Zwijnaarde, Belgium.

95 ³ Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, U.K.

96 ⁴ School of Biological Sciences, Institute for Global Food Security, Queen's University Belfast,
97 BT9 5DL Belfast, Northern Ireland, U.K.

98

99 **Of the many metabolites that are are involved in any clinical condition, only a narrow**
100 **range of biomarkers is currently being used in the clinical setting. A key to personalised**
101 **medicine would be to extend this range. Metabolic fingerprinting provides a more**
102 **comprehensive insight, but many methods used for metabolomics analysis are too**
103 **complex and time-consuming to be diagnostically useful. Here, a rapid evaporative**
104 **ionization mass spectrometry (REIMS) system for direct *ex vivo* real-time analysis of**
105 **biofluids with minor sample pre-treatment is detailed. The REIMS can be linked to various**
106 **laser wavelength systems (such as OPO or CO₂ laser) and with automation for high-**

throughput analysis. Laser-induced sample evaporation occurs within seconds through radiative heating with the plume guided to the MS instrument. The presented procedure includes (i) laser set-up with automation, (ii) analysis of biofluids (blood/urine/stool/saliva/sputum/breast milk), and (iii) data analysis. We provide the optimal settings for biofluid analysis and quality control, enabling sensitive, precise and robust analysis. Using the automated set-up, 96 samples can be analysed in ca. 35-40 minutes per ionization mode, with no intervention required. Metabolic fingerprints enclose about 2000 to 4000 features, for which relative quantification can be achieved at high repeatability when total ion current normalization is applied. With saliva and feces as example matrices, more than 70% of features had a coefficient of variance $\leq 30\%$. However, to achieve acceptable long-term reproducibility, additional normalizations by *e.g.* LOESS are recommended, especially for positive ionization.

Introduction

To date, metabolic fingerprinting of human biological fluids is most typically accomplished through high-resolution mass spectrometry (HRMS) in hyphenation with a chromatographic separation technique such as capillary electrophoresis, liquid or gas chromatography^{1,2}. This analytical approach allows for the sensitive and selective measurement of low-molecular metabolites (< 1500 Da), generating a metabolic read-out that can be used to gain interesting insights in biological and (patho)physiological processes^{3,4}. More specifically, biomarker metabolites and biological pathways can be shown to be associated with particular phenotypes of human health and disease⁵. This approach does, however, have some substantial shortcomings that strongly restrict the general application potential; *i.e.* protocols are often laborious and involving elaborate sample preparations, which contribute

to relatively low sample throughput rates and high costs as well as a significant risk for artefacts such as metabolite degradation, causing variable or poor recovery². These requirements and limitations mean that metabolic fingerprinting by hyphenated HRMS is not practical for *e.g.* point-of-care testing in clinical practice. Indeed, in that setting, there is a high need for simplicity and automation to analyze large sample batches, there is only limited time for sample analysis, the measurements are of an individualized nature, and the physical sample size available is often limited^{6,7}.

It is therefore productive to explore alternative analytical strategies such as ambient ionization mass spectrometry that are able to produce metabolic fingerprints, but that don't require extensive sample preparation or chromatographic separation. With ambient ionization techniques, samples are analysed in their native environment or after minimal pre-treatment; and gas-phase ions are generated under open-air conditions and directly introduced into the mass spectrometer^{6,8}. Traditionally, ambient ionization has been achieved through various desorption ionization methods such as ambient pressure matrix-assisted laser desorption (AP-MALDI), direct analysis in real-time mass spectrometry (DART-MS), desorption electrospray ionization (DESI), and secondary ionization mass spectrometry (SIMS). These approaches have been used successfully in the analysis of intact (*ex vivo*) biological tissues, but are not suitable for ionising living tissues. There, thermal evaporation techniques have become the norm, including thermal electrosurgery and laser surgery^{9,10}. These have mostly been used to determine the position of the borders between malignant tumours and healthy tissue¹¹.

Only recently, laser assisted ambient ionization mass spectrometry (LA-REIMS, laser assisted rapid evaporative ionization MS) has also been exploited (by the authors of this paper) for rapid, real-time fingerprinting of various human biofluids, *i.e.* saliva, urine, feces, sputum,

155 breast milk and plasma^{7,12,13}. In this approach, the process of laser ablation is based on the
156 laser-emitted infrared wavelength regime that excites the most intense vibrational band
157 (oxygen-hydrogen stretching mode) of the water molecules that are highly present in the
158 respective biological fluids, initiating matrix-assisted desorption and ionization of intact
159 biomolecules¹⁴. It should be noted that, in comparison with other techniques, laser assisted
160 ionization does not require the usage of solvents (versus *e.g.* DESI), high voltages or gas
161 flows (*e.g.* DART, 2 to 4 kV discharge needle voltage and 1.5 to 3.0 L/min gas flow rate), nor
162 does it require direct contact with the sample (*e.g.* hand-held sampling devices such as the
163 iKnife that are typically used to cut through tissue and rapidly heat it, to generate a vapor)⁷.
164 The approach that is used in this protocol is very similar to the iKnife, but the fact that there
165 is no probe that has direct contact with the samples means that the cleaning requirements
166 and the risk of sample-to-sample contamination are substantially lower. These are
167 considered essential conditions for platform automation.

168 In LA-REIMS , no pre-treatment is needed for the analysis of fresh feces, urine, plasma,
169 breast milk and sputum, and only centrifugation and filtration are required for saliva
170 analysis. As such, fingerprinting of biofluids by LA-REIMS could generally be achieved within
171 less than 1 min per sample^{7,12,13}. In addition, we assume that artefactual metabolite
172 modifications are less likely to occur in experiments with fewer sample processing steps and
173 shorter analytical times. In comparison with hyphenated techniques, LA-REIMS has
174 substantially fewer analytical biases relating to sample pre-treatment, extraction and
175 storage (*i.e.* samples are analysed in or very close to their native condition), or resulting from
176 chromatographic and mass spectrometric drifts (*i.e.* the analysis times are much shorter).

177 Without chromatographic separation, however, metabolome coverage is likely to be lower
178 as characterization of metabolite-associated features is based on mass measurements only.

As such, it will for example not be possible to separate isomers and isobars. This also limits the possibilities for quantification. Data from LA-REIMS are thus not as comprehensive as those from conventional metabolic fingerprinting approaches (*i.e.*, UHPLC-HRMS)⁴. In addition, secondary ionization of ablated metabolites at the rapid evaporative ionization (REI) collision surface may also suffer from ion suppression, which has adverse effects on sensitivity and quantification accuracy¹⁵. As such, biofluid metabolomics by LA-REIMS may primarily find acceptance in first-line segregation of samples based on distinctive fingerprints and according to (patho)physiological state, as has been demonstrated by a number of clinical studies^{7,12,13}. For a more detailed read-out of the metabolome, conventional hyphenated techniques can be used to achieve advanced separation and in-depth characterization as well as quantification of metabolites.

Laser ablation ambient ionization mass spectrometry has also been described for rapid metabolic fingerprinting of tissue (*e.g.* by Fatou et al., 2016)¹⁴ and is the subject of another Nature Protocol (*i.e.*, Ogrinc et al., 2019)⁸. This manuscript, therefore, focuses on rapid metabolic fingerprinting of biofluids and captures the experience gained in multiple studies published by the involved authors. Key procedural differences are found at many stages of the protocol: at the level of the instrumental set-up (*e.g.* the need for a T-shaped connector piece at the REI-source to concentrate the low metabolite concentrations as present in the aerosol), instrumental settings (both with respect to the laser as well as the REI-mass spectrometer) as well as biofluid sample handlings (*e.g.* specific volumes, pre-treatments, and cleaning procedures). This work also describes how to adapt the method for automation.

***Ex vivo* direct biofluid molecular fingerprinting using LA-REIMS**

The LA-REIMS methodology (Fig. 1) comprises direct ablation following laser irradiation and subsequent aerosolization from the sample surface under analysis. In this protocol, an Nd:YAG laser (operating wavelength of 2.94 μm) and CO_2 laser (operating wavelength of 10.64 μm) for laser irradiation are described. A detailed comparison between these laser types can be found in the study of Schäfer *et al.* (2011)¹⁶ that reported on the reproducibility of analysis, induction of photochemical processes, coagulative properties, and uniformity of the generated mass spectra according to wavelength, specifically assessed for tissue. For biofluid analysis, own research indicated the suitability of both laser types to achieve comprehensive metabolic fingerprinting, however, without having made explicit comparisons. The energy of the emitted infrared laser beam is absorbed by the water molecules, abundantly present in the biological matrices, as a result of the stretching vibrations of the hydroxyl groups¹⁷. This desorption and ionization mechanism has the unique advantage of being able to exploit the presence of abundant endogenous water^{18,19}. The setup also features an MS-source (i.e., REI-source) that is specifically designed to efficiently draw the produced aerosol through an aerosol vent transmission tube (millisecond timescale) into the deep vacuum region of the MS-instrumentation. This tube interfaces the MS-source by means of an orthogonally mounted T-shaped connector piece and designated insert that is surrounding the aerosol inlet tube. In the source, declustering of the aerosol, comprising desorbed droplets of both positive and negative analyte ions, takes place by collision onto a heated impactor, whereby individual molecular species are generated. Therefore, LA-REIMS is a two-step technique involving desorptive release of the chemical components and secondary ionization mechanisms¹⁸. Ionization is assisted by a solvent matrix, for example isopropylalcohol, that is provided at the REI-source²⁰. This solvent plays a MALDI-like role in that it reduces intermolecular forces and improves ion

formation. More specifically, the polar protic nature of isopropylalcohol is useful in dissolving lipid species and as such, enables the formation of individual molecular ions via a collision driven ion release mechanism (heated impactor) which ultimately enhances the signal-to-noise ratio²¹. Moreover, aerosol dilution reduces fouling at the inlet capillary resulting in better spectral classifications and allowing the instrument to run under high-throughput conditions. The flow rate of the solvent matrix is optimized for every biological matrix type (*e.g.* 150 μ L/min for feces) and can contain a 'lock mass' external calibration compound (*e.g.* 10 ng/mL leucine-enkephalin).

As a measure of securing consistency in the analysis process through reduction of operator-related factors and to further increase the analysis speed, an automated versatile multiwell plate-based platform was incorporated in the standard REIMS workflow. The latter serves to introduce fully remote and automated fingerprinting of a large number (up to 576) of small volumes of biological material in a fraction of time. Additionally, as positioning the samples inside the restricted area of each well results in a more uniform sample distribution compared to the open area of the microscope slide, the microplate configuration contributes further benefits to standardization of analyses. A flowchart (Fig. 2) presenting the entire procedure from sample collection to data processing is provided.

Applications of the method

Whereas blood is the most sampled biofluid in clinical research, diverse alternatives are available that can be accessed non-invasively and offer an at least equally rich and chemically diverse metabolome coverage, reflective of various biological processes. Among those are urine (a key harbor of metabolic waste products¹¹ addressed in *e.g.* illicit drug screening), saliva (parallels metabolic alterations occurring in blood and applied in studying

e.g. obesity²²), stool (ideally suited to study the diet-microbiome-metabolome axis in gastro-intestinal disorders, *e.g.* type 2 diabetes²³), and sputum (a means to study bacterial activity within the airways, *e.g.* in cystic fibrosis²⁴). LA-REIMS provides an almost instantaneous fingerprinting strategy without (or hardly) damaging the analysed biofluids and as such allows for cross-evaluation with conventional methodologies. In this regard, the LA-REIMS platform described presently, has recently demonstrated rapid fingerprinting of saliva and feces, each complemented by metabolic profiling and cross-evaluation against established UHPLC-HRMS metabolomics and lipidomics platforms^{4,25,26} for in-depth biological interpretation. The ambient *ex vivo* analysis of both cited biofluids allowed the establishment of validated multivariate models that were predictive for assigning metabolic perturbations according to pathophysiology, *i.e.* weight and glycaemic state, and provided general classification accuracies of 97.1% and 90.5%, respectively⁴. Thus, LA-REIMS represents an expedient strategy in first-line distinctive metabotyping based on easy to obtain biofluids¹².

Limitations and potential improvements of the protocol

The LA-REIMS method presented here suffers similar limitations as many other methods in the field of ambient ionization mass spectrometry and wider fields of direct and flow infusion MS²⁷. These limitations arise from the removal of chromatographic separation of the chemical contents of a sample, prior to ionization. For LA-REIMS, this means that ion formation for a sample's metabolic fingerprint is condensed into a two to eight second time frame compared to hyphenated methods, such as LC- and GC-MS, where molecules are introduced for ion generation over a typical 10 to 20 minute period⁷. Due to ion suppression effects, this will likely result in a lower sensitivity of the LA-REIMS method compared to

hyphenated methods, even when the same high resolution mass spectrometer is used for analysis. The usage of internal or external standards may provide a relevant strategy to address this issue, although it is not possible to reach sufficient representativeness for all metabolome constituents. In addition, the lack of chromatographic separation also hampers the structural identification of features. Indeed, without having retention time as an orthogonal separator, it is not straightforward to cluster different m/z -features that are originating from the same metabolite (*e.g.* $[M+H]^+$ and $[M-H_2O+H]^+$ ionization adducts) nor is it possible to distinguish metabolites that are represented by identical or similar m/z -values (*i.e.*, isobars or structural and stereoisomers)²⁸. This can be somewhat overcome through usage of the instrument's tandem MS functionality and the consultation of repositories with fragmentation data. However, interpretation of fragmentation data is not evident as metabolites with identical or similar m/z -values will be subjected to the the same selection and fragmentation event, resulting in intertwined fragmentation m/z -spectra. Moreover, the inclusion of fragmentation scan events during the short period of the burn is at the expense of the full-scan events, which may have adverse consequence for the sensitivity and quantification accuracy. Hence, the information that is obtained from chromatographic separation and that is supportive for identification cannot be easily replaced. One strategy to improve the analytical resolution of LA-REIMS, being equivalent to chromatographic separation, could be the application of ion mobility separation²⁹. As separation occurs on the millisecond scale, it complements the method's rapid analysis time and provides a second dimension to analytical resolution. Moreover, it does not interfere with the full-scan events. Usage of ion mobility would, however, add extra complexity to instrumental operation and maintenance, which not fully aligns with the purpose of LA-REIMS to translate metabolomics into clinical practice and for point-of-care implementations. In this respect, as earlier noted,

LA-REIMS is merely proposed as a strategy for first-line segregation of samples, without in-depth biological-mechanistic explorations.

Further benefits to the LA-REIMS method could be achieved through alternative means of sample heating and evaporation, particularly with regard to the pulsatile and wavelength characteristics of lasers. It may be possible to target specific chemical classes through optimisation of laser choice, reducing ionization competition and improving analytical sensitivity. Similar benefits could be pursued through modification of the solvent matrix including different polarities, or through the addition of additives to enhance the ionization of particular analytical targets³⁰.

Experimental design

Sample preparation

The method allows for the analysis of freshly collected as well as thawed specimens (Box 1). If samples cannot be analysed immediately upon collection, storage at -80 °C is recommended to preserve the metabolic fingerprint. Aside from temperature conditions, maximal storage duration should be considered when designing the experiment as well^{31,32}. Liquid samples can be aliquoted and frozen without treatment, while semi-solid matrices (such as feces) should preferentially undergo lyophilisation³³ prior to storage.

Quality control samples

In addition to samples under investigation, external quality control (eQC) samples should be prepared for instrument conditioning and internal quality control (iQC) samples for monitoring instrumental performance and possible data normalization. For cohort studies, these QC sample can be prepared by aliquoting and thoroughly mixing equal volumes from a selection of representative samples (*i.e.*, including the assessed disease states, age

categories, treatments, *etc.*) or, preferably, from all biological samples. The final volume of the QC blend should allow to include ten eQCs per ionization mode at the beginning of the sequence and two iQCs every 20 to 40 analytical runs (depending on batch size and available sample volume)¹². On the other hand, a reference material that is not directly derived from the sample batch for analysis can be used as well, being self-assembled from any excess experimental samples or commercially available (*e.g.* pooled human serum, MP Biomedicals, cat.no 2930149). This may be particularly useful for discontinuous LA-REIMS analysis of samples across several analytical batches, *e.g.* for general metabotyping or specific diagnosis of patients.

BOX 1 | Sample preparation • **Timing** 0-15 min

This box describes sample handling and preparation for analysis of freshly collected as well as previously frozen samples.

! CAUTION When using human samples in experimental settings, all necessary local and global ethical regulations should be fulfilled.

Additional materials

- Plastic microcentrifuge tubes (2 mL, Eppendorf, Germany, cat. no. 0030120094)
- Microcentrifuge (MicroCL 17, Thermo Fisher Scientific, USA, cat. no. 75002406)
- Analytical balance (ML104T/00, Mettler Toledo, USA, cat. no. 30243394)

- 1 mL Luer slip syringes (Becton Dickinson, USA)
- Polyamide membrane filters (CHROMAFIL®, 13 mm diameter, 0.45 µm pore size; Macherey-Nagel, Germany, cat. no. 91652)
- Sartorius Arium 661 UV water purification system (Sartorius, Germany, cat. no. H₂OPRO-UV-B-TOC)
- Vortex shaker IKA vortex genius 3 (IKA-Werke GmbH & Co. KG, Germany, cat. no. 0003340000)

Procedure

▲ **CRITICAL STEP** All frozen samples should be defrosted at 4 °C shortly before described pre-treatment procedures.

Saliva

1. Vortex raw samples (freshly collected or defrosted) during 30 s at 400 x g and room temperature (25 °C) to ensure homogenization.
2. Transfer 450 µL of each sample into separate microcentrifuge tubes.
3. Centrifuge at 17 000 x g for 5 min at room temperature.
4. Collect all resulting supernatant in 1 mL syringe and pass through polyamide membrane filter into new microcentrifuge tube. This can be analysed immediately or stored at -80 °C, preferably for less than 1 month³⁴.

Feces

1. Freshly collected stool samples can be homogenized manually with a sterile spatula or

using commercially available homogenizers (*e.g.* Stomacher®) according to manufacturer guidelines. Following homogenization, these samples are ready for LA-REIMS analysis.

2. If prolonged storage of fecal samples is required, consider lyophilising the samples.

They can then be stored at -80 °C, preferably for less than 2 months³¹.

3. When preparing the lyophilised samples for LA-REIMS analysis:

(i) Weigh 200 ($\pm$ 1) mg of lyophilized homogenized feces in 1.5 mL microcentrifuge tube.

(ii) Add 600 μ L of ultrapure water.

(iii) Thoroughly mix by vortexing for 60 s at 400 x g (if homogeneity is not achieved, additionally a sterile spatula may be used) and keep at 4 °C prior to analysis.

Urine and blood plasma

1. Freshly collected samples do not require any pre-treatment. If analysis is not performed immediately, samples can be stored at -80 °C for preferably less than 1 month^{35,36}.

2. Defrosted samples require a homogenization step, by vortexing at 400 x g for 30 s and keep them at 4 °C prior to analysis.

Human milk

1. Homogenise freshly collected samples by vortexing at 400 x g for 30 s. These can be analysed directly or frozen for storage at -80 °C for preferably less than 3 months³⁷.

Vortex after defrosting at 400 x g for 30 s and keep at 4 °C prior to analysis.

2. If the analytical focus is fat and complex lipids, perform refrigerated centrifugation (4 °C) for 5 min at 3000 x g to create a fat layer that can be directly analysed by LA-REIMS. If required, the fatty layer can be removed from the aqueous phase with a sterile single-use 10 μ L microbiological inoculating loop and transferred to a sterile microcentrifuge tube for separate analysis.

Sputum

1. Freshly collected samples do not require any pre-treatment. If analysis is not performed immediately, frozen samples can be stored at -80 °C for at least 1 month³⁸. Defrost at 4 °C prior to LA-REIMS analysis.

C. If desired for easier homogenization of the sample matrix, sputum can be treated with Sputasol (#SR0233, Oxoid, ThermoFisher Scientific, USA) following standard manufacturer's instructions. This can be completed on freshly collected samples prior to analysis or prior to storage at -80 °C. Homogenisation may be necessary where visible colour heterogeneity exists within the sample or variations in consistency across the sample is noted, and which is not resolved through vortex mixing. During experimental design, consideration should be given to whether sample homogenization with Sputasol should be undertaken regardless of sample appearance as it would be a likely source of bias to only treat a selection of samples.

Quality control samples

1. Define how many analytical runs will be considered for the LA-REIMS experiment and calculate how many QC runs are needed. Guidelines regarding the number and frequency of eQC and iQC samples have been defined previously (section 'Quality control samples').
2. For determination of the total volume needed, take into account the recommended starting-volumes per matrix type (see section 'Procedure' below) and consider a separate glass microscope slide / well for every QC run.
3. Establish a QC-pool by taking equal aliquots from (a selection of) representative samples or by considering general reference material. Vortex the QC-pool

thoroughly.

4. Store the QC-pool at -80 °C if LA-REIMS analysis is performed, either continuously or discontinuously, for several days. Consider aliquoting of the QC-pool for storage, in order to avoid freeze-thaw cycle effects.

333

334 **LA-REIMS system set-up**

335 **Laser set-up**

336 **MID-IR laser:** The installation used comprises a MID infrared laser system (Opolette™
337 HE2940, OPOTEK LLC, USA) consisting of a Q-switched Nd:YAG laser pumping Optical
338 Parametric Oscillator (OPO). The system output is fixed at 2.94 µm wavelength, 6 mJ peak
339 OPO energy, 7 ns pulse duration and 20 Hz repetition rate. Q-switch delay time is a tunable
340 parameter with a direct impact on the transferred laser energy. The delay time may be
341 optimized for each biofluid matrix separately depending on the produced peak intensity and
342 repeatability, ranging between 165 and 180 µs (see 'Equipment set-up' section). The OPO
343 beam transmission and focusing on the sampling area is achieved by the free space steering
344 optics consisting of 3 metallic-coated mirrors and a plano-convex lens placed directly above
345 the sampling surface. The sampling area position 5.5 cm below the focusing lens as well as
346 the laser focusing optics represent a fixed construction and, once set and aligned, do not
347 require routine tuning before each experiment. Laser beam and external optics alignment
348 verification, however, have to be performed on any new installation and systematically
349 checked (Box 2).

350

351 **CO₂ laser:** This is typically a modified surgical CO₂ laser, operated at a 10.6 µm wavelength.
352 Previous publications have utilised an OmniGuide FELS-25A (OmniGuide, Massachusetts,

USA) or Aesculight VetScalpal (Aesculight, Washington, USA) using either mirror optics or a hollow core fibre for laser beam transmission. A single mirror focusing handpiece is used to direct the beam to a spot size of ca. 500 μm . These surgical CO₂ lasers are used as they have been created for the cutting and cauterising of animal tissue, and their wavelength and absorbance profiles are thus complementary to the analysis of biological materials. They are typically at the lower end of CO₂ laser powers (<10 W) which are commercially available, particularly when compared to industrial CO₂ lasers (>100 W) used for cutting/engraving applications. Optimisation of CO₂ laser power and delivery can be carried out for different biological materials by altering the power output, pulsatile window, and distance between focusing lens and sample. The output of the CO₂ laser should be periodically checked with an appropriate power monitor (such as Pronto-250-PLUS, Gentec Electro Optics, Quebec, Canada) to ensure output is within the expected range.

BOX 2 | MID-IR laser alignment verification procedures • Timing 20 – 30 min

This box describes laser alignment and routine alignment verification for the MID-IR OPO laser. Alignment of the CO₂ laser follows a similar principle.

! CAUTION Always wear eye protection with sufficient optical density while operating the laser. Consult Class 4 laser safety measures and equipment manual for additional precautions while operating the installation.

Additional equipment

- MIR Detector Cards: 1.5 to > 13.2 μm (Thorlabs GmbH, Germany)
- Optical alignment target (shipped with Opolette™ HE2940 MID-IR laser system)

Procedure

Laser alignment verification

▲ **CRITICAL** Beam alignment has to be performed on a new installation and assessed periodically following manufacturer recommendations or whenever laser misalignment is suspected (*e.g.* you have moved the setup).

1. On the front panel of the Opolette laser head, expose the laser pump port by moving the shutter marked '1064' to the side.
2. Screw the optical alignment target to the port with the uncovered area up (thus allowing visualization of the alignment target interior).
3. Set Q-switch delay time to 320 μs in the Q-switch configuration menu within laser control software or on handheld remote controller panel.
4. Activate the laser beam by consecutively pressing the 'Start' buttons on the flash lamp and Q-switch sections of the remote control/control software. The green light should appear around the alignment target aperture.
5. Check the position of the green light beam on the alignment target aperture. If the beam is centred, the laser is aligned and can be safely operated. Otherwise contact OPOTEK support centre.
6. Press the 'Stop' button subsequently on the flash lamp and Q-switch sections of the remote control/control software to deactivate the laser.

? TROUBLESHOOTING

! CAUTION Do not decrease Q-switch delay time below 300 μs while aligning as it may damage the alignment verification target.

! CAUTION Do not further operate the system if the laser is misaligned or if the correct alignment cannot be verified.

External optics alignment verification

▲ CRITICAL Correct alignment of the laser steering optics is required for sufficient energy transmission and is crucial for operator safety.

7. To activate the alignment diode, toggle the switch at the back of the laser pump case.

The red light will become visible as projected on the sampling surface guided by the set of metallic-coated mirrors.

8. Check the projected position of the diode light on the working surface: the beam should pass through the middle of the focusing plano-convex lens. If not, adjust the positions of the metallic-coated mirrors.

9. Set the laser system in the operation mode as described in step 2 of the protocol.

10. Place the thermosensitive MIR detector card underneath the focusing lens so that the projected alignment diode light is visible on the card's surface.

11. Activate the laser beam by pressing the 'Start' button subsequently on the flash lamp and Q-switch sections of the remote control/control software.

12. The area of the discoloration on the MIR detector card will indicate the projection of the laser beam and that position should overlap with the alignment diode projection.

13. Deactivate the laser by consecutively pressing the 'Stop' buttons on the Q-switch and

flash lamp sections of the remote control/control software.

14. Toggle the switch at the back of the laser pump case to deactivate the alignment diode.

366

367 **LA-REIMS sample analysis**

368 As a measure to ensure accurate laser energy transmission to the sample, it is essential to
369 establish the correct position of the laser optics and/or sampling area prior to analysis in
370 such a way that the laser focus point lays within the surface or the top layer of the specimen.
371 Besides, as the laser focusing lens is positioned merely 5 cm above the sampling surface and
372 hence prone to contamination resulting from the ablation process, it is important to monitor
373 and assure its cleanliness during the analytical runs. In particular, the state of the lens should
374 be evaluated every 5 to 10 ablations⁴, depending on the sample type. When contaminated,
375 the lens should be cleaned with a cotton swab drenched in ethanol. Interestingly,
376 positioning samples in a microtiter plate (automated sampling, see below) instead of on
377 glass microscope slides (manual sampling, see below) reduces the distribution of liquid
378 splashes during ablation and the resulting focusing lens contamination, hence the frequency
379 of cleaning. In case of automated sampling using microtiter plates significant focusing lens
380 contamination and associated decrease in MS signal intensity (with more than one order)
381 has been observed only after 30 to 50 ablations (depending on the matrix type under study).
382 Nevertheless, we recommend lens cleaning to be performed at least every 5 ablations
383 during manual sampling and every 12 ablations during automated sampling to anticipate any
384 possible signal issues (Step 30 of the protocol).
385 For the manual analysis, 20 to 50 μ L of the liquid biofluid (or thin layer of fecal blend) is
386 pipetted on a glass microscope slide. Next, the slide is manually transferred under the laser

beam focusing point and irradiated for 3 s and removed. In between sample ablation, the solvent signal is recorded for 3 to 4 s to ensure that the signal intensity drops to the background level and guarantee good peak resolution (Fig. 3). The method acquisition time is set to 30 s per sample which is sufficient to generate 2 to 3 technical replicates (ablations) within one acquisition period, if desired¹².

The automated sampling platform employs a simple in-house made two-axis (XY) motorised precision position stage (Fig. 4a) that can hold up to 6 different 96-well plates on the mobile platform. The customized controlling software defines the platform movements and laser activation/deactivation sequence. The moving stage subsequently positions the samples in the separate wells under the laser focusing point. Every irradiation (ablation) is followed by a cooldown period during which the next well is positioned below the laser focusing point and a new acquisition datafile is initiated by the recording software. The sample volume within each well is recommended to be at least 50 and up to 100 μ L as bigger volumes are better preserved during prolonged exposure of the liquid samples to ambient conditions during automated analysis as opposed to manual sampling. Although the recommended sample volume is substantially higher when using automated sampling compared to manual sampling, the (semi-)liquid within the well plates can be subjected to repeated laser ablations without loss of signal intensity or spectrum quality (Table 3). An additional measure that can be taken to minimize passive evaporation of the specimens within the wells during analysis, is the installation of a local thermoelectric (Peltier) cooling element in the sampling area to create an optimal (cooled) microenvironment.

Daily calibrations of the MS instrument during active sample analysis periods should be performed according to manufacturer guidelines to ensure the highest mass accuracy (*e.g.* sodium formate solution in 90:10 isopropylalcohol:water (v/v) for calibration of Waters

QToF/Q-IMS-ToF instruments)^{7,12}. Moreover, when starting the instrument after cleaning or planning sample analysis for different matrices, it is advised to run 10 to 20 pooled eQC samples in both ion modes to secure adequate instrument conditioning before starting the analysis or switching to another matrix type¹². This measure reduces initial signal drift within the samples of interest during the actual experiment. A representative number of iQC samples (two between every 20 to 40 analytical run) should be analysed to monitor and compensate for possible MS signal output changes during the analytical run (analytical drift). A final strategy to ensure the quality of collected data is the usage of external standards infused together with the solvent matrix (*e.g.* leucine-enkephalin⁷ or a combination of palmitic acid-d₃₁ and 1,2-dimyristoy-d₅₄-*sn*-glycero-3-phosphocholine¹²). This allows for evaluation of instrument analytical performance as well as lock mass correction and data normalization.

LA-REIMS data collection

Data collection is performed using MS vendor-specific software. All MS methods for automated programs are set at 18 s per sample acquisition time, while 30 s is used upon manual sampling⁴. Mass spectra can be collected as one raw data file per sample, which may reduce downstream data processing but increase time for data collection. Alternatively, one raw data file per microwell plate or batch could be generated, which may then decrease time for data collection as a result of reduced instrument electronic control but requires the splitting of files and thus increases subsequent downstream data processing.

Data analysis & classification modelling

Data analysis can be performed using any kind of software that runs the appropriate sort of algorithms. Box 3 describes the procedures that were followed, using the software that was available to the authors of this protocol.

During LA-REIMS analysis, molecular fingerprints are acquired by MS vendor-specific software, such as MassLynxTM (v4.2, Waters, stored as .raw directories) in case of Waters instruments. Prior to performing classification modelling, several pre-processing steps are implemented to select representative burns, subtract background and noise, and perform peak picking (Box 3, Steps 1-12). In general, these pre-processing steps are also executed using vendor-specific software (Progenesis[®] Bridge, Progenesis[®] QI, AMX or Live ID, Waters). Alternatively, spectra can be pre-processed using freely available open-source metabolomics software such as XCMS³⁹, MZmine⁴⁰, *etc.*

Following pre-processing, peak lists of *m/z*-features are subjected to multivariate statistical analysis, typically including principal component analysis (PCA⁴¹) and orthogonal partial least squares discriminant analysis (OPLS-DA⁴²) (using software packages such as SIMCA (v15, Sartorius)) (Box 3, Steps 13-22). PCA serves as an unsupervised dimension reduction technique to investigate variance within the dataset. OPLS-DA is a supervised regression methodology whereby user-defined groups are taken into account, thereby pursuing classification of the groups based on discriminative features. The (validated) models can be utilized to extract discriminative features that can further undergo identification using fragmentation experiments and database matching.

In Box 3, data analysis and classification modelling from raw files collected on the LA-REIMS instrument (Waters), is described by the sequential use of Progenesis[®] Bridge (v1.0.29, Waters), Progenesis[®] QI (v2.1, Waters) and SIMCA (v15, Sartorius) software.

BOX 3 | LA-REIMS data analysis & classification modelling • Timing 1 h for ca. 500

samples

This box describes the pre-processing and classification modelling (steps 31-34 of the Procedure) that is performed after data acquisition by LA-REIMS. This biostatistical pipeline can be used for any type of analyte described in this protocol, and uses three commercially available software packages.

The first program, Progenesis[®] Bridge (v1.0.29, Waters), is capable of handling Waters MS .raw directories and performs background subtraction, lock mass correction (optional), creates extracted ion chromatograms for each burn and separates multiple burns in each raw folder into individual raw folders. This separation enables individual burns to be treated as individual samples. For further treatment in Progenesis[®] QI, all individual peak raw folders can be loaded or 1 peak per sample can be selected. In case of the latter, it is suggested to use the peak with the highest total ion current (TIC) value. TIC can be assessed by manually inspecting each chromatogram in MassLynx[™] (Waters).

Next, the raw data are ready for importing into the second software program, Progenesis[®] QI (v2.1, Waters), where peak picking and TIC normalization is performed and lists of *m/z*-features are generated. In a third software program, SIMCA (v15, Sartorius), fingerprints can be visualised, quantified and statistically classified, and discriminating features can be defined. The data analysis pipeline consists of the steps summed below.

Procedure

1. Open Progenesis[®] Bridge, fill in fields a. to d., as described below, and click 'Run'.
 - a. Source: directory path containing non-processed Waters .raw directories.
 - b. Output path: directory path where processed data will be stored.
 - c. TIC replicate threshold: threshold between background and peak intensity.
Should be set at approximately 1/3 of peak height.

? TROUBLESHOOTING

 - d. Lock Mass Correction: None.
2. Open Progenesis[®] QI, click 'File' > 'New' and fill in experiment name and directory path.
3. Set the analysis parameters of new experiment a. to c., as described below, and click 'Next'.
 - a. Type of machine: direct sample analysis.
 - b. Data format: profile data.
 - c. Ionization polarity: select correct polarity according to the experiment.
4. Select the possible adducts according to the experiment and click 'Create experiment'.
5. In the created experiment window, in tab 'Import Data', choose Waters (.raw) format and click 'Import' to select and import files that need to be processed.
6. In the created experiment window, in tab 'Import Data', click 'Start automatic processing'.
 - a. Experimental design can be left empty at this stage, click 'Next'.
 - b. Set the peak picking parameters by clicking 'Set parameters', fill in and click 'OK'.

- i. Peak picking limits > Sensitivity: Automatic – default.
 - ii. For the other parameters, default values should be attained.
7. In the created experiment window, in tab 'Experimental Design Setup', click 'Between-subject Design', fill in and click 'Create design'.
 - a. Design: new design.
 - b. Group runs manually.
 - c. Create design.
8. In the created experiment window, in tab 'Experimental Design Setup', select all samples, click 'Add Selected Runs to Condition'.
9. In the created experiment window, in tab 'Peak Picking', click 'Review Normalisation', click 'Normalisation Method' and select 'Normalize using total ion abundance'.
10. In the created experiment window, in tab 'Review Compounds', check information of compounds.
11. Click 'File' > 'Export compounds measurements', select information to export and click 'OK'.
 - a. Select Compound, m/z , normalized abundance, raw abundance.
12. Transpose, rearrange and add classification labels prior to loading peak lists into SIMCA. Optionally, (internal) quality control normalization can be performed during this step.
13. Open SIMCA, click 'File' > 'New' > 'Regular Project'.
14. Paste the data from the .csv file into the 'SIMCA Import' window.
15. Create workset by defining the data, click 'Finish import'.

- a. Define the row head as 'Primary ID'.
- b. Define the column head as 'Primary ID'.
- c. Define the 2nd column head to select a data type 'Y variable with Qualitative Data' or 'Y with Quantitative Data'; depending on the experiment type.

? TROUBLESHOOTING

16. In the 'Home' tab, click 'Change model type' > 'PCA-X model'.
17. In the 'Home' tab, Click 'Edit' to control the PCA settings, click 'OK'.
 - a. Click tab 'Scale', select all and choose type: *e.g.* Par (Pareto scaling).
 - b. Click tab 'Transform', select all, choose 'Specify transformation': Log, click 'Set', select box 'If one variable in the X or Y block needs transformation, transform all selected variables in that block' and click 'Transform'.
18. In the 'Home' tab, Click 'Autofit' and 'Scores' to visualize model.
19. In the 'Home' tab, Click 'New as' > 'PCA-X' (copy settings previous model), click 'OK'.
20. In the 'Home' tab, click 'Change model type' > 'OPLS-DA model'.
21. In the 'Home' tab, Click 'Edit' to control the PCA settings, click 'OK'.
 - a. Click tab 'Observations' to check classes are selected; if not: select samples per class, name the new class and click 'Set'.
 - b. Click tab 'Observations' to exclude samples (*e.g.* QCs): select sample and click 'Exclude'.
22. In the 'Home' tab, Click 'Autofit' and 'Scores' to visualize model.

457

458 **Materials**

459

460 **Biological materials**

461 • *Stool samples:* For development of the LA-REIMS procedures as well as to perform rapid
462 fingerprinting in a context of clinical diagnostics, stool samples were collected from study
463 participants that provided written, informed consent, following approval of the study by
464 the ethics committee. For the examples described in this protocol, samples were
465 collected under University Hospital Ghent Ethical Committee (EC 2016/0673). Collection
466 of stool material is preferable performed by using specifically designed equipment, such
467 as *e.g.* the Fecotainer® or FecesCatcher (De Fecesvanger, The Netherlands; both of these
468 products provide detailed instructions. Other tools (*e.g.* plastic bag, plastic disposable,
469 bucket, *etc.*) are also suitable although considered less convenient for the study
470 participant. Upon collection, fresh stool samples should immediately be frozen at -80 °C
471 if possible, *i.e.* if sample collection takes place at *e.g.* the hospital, research facility, *etc.* If
472 the sample is collected at the participant's home, temporary storage at -20 °C will be
473 needed, but should be kept as short as possible. Transport of the sample to the relevant
474 facilities should be realized under cooled conditions (0 °C or lower; using ice packs, dry
475 ice, or liquid nitrogen). Prior to storage at -80 °C, lyophilization is advised in order to
476 remove water and stop microbial activity. In this study, lyophilization was achieved by
477 placing the samples in a Christ 1-4 Alpha LSC*plus* lyophilisator for 48 ± 4 h at -40 °C.
478 Lyophilized samples were grinded with pestle and mortar and sieved (mesh size of 2.5
479 mm) to obtain a homogenous powder.

480 To demonstrate the application potential of LA-REIMS stool fingerprinting in a clinical
481 context, stool material was collected from male and female study participants with
482 normal blood glucose levels and those that were diagnosed with type 2 diabetes,

thereby applying a classification threshold of 60 mmol/mol glycated haemoglobin (Hb A1c).

<CRITICAL> It is important that stool material is not contaminated with urine during its collection. <CRITICAL> Fresh (non-lyophilized) samples should be kept frozen at all times to avoid metabolic alterations.

- *Blood samples (plasma)*: For development of the LA-REIMS procedures as well as to perform rapid fingerprinting in a context of clinical diagnostics, blood samples were collected from study participants that provided written, informed consent, following approval of the study by the ethics committee. For the examples, described in this protocol, samples were collected under University Hospital Ghent Ethical Committee (EC 2016/0673).

Blood samples were collected from the study participants using a 10-mL syringe and transferred into a heparin-containing tube, which was centrifuged for 10 min at 2800 to 3000 x g (at 2 – 8 °C). The obtained plasma was transferred to a cryovial and stored at -80 °C. If needed, transport of the plasma samples should be realized under cooled conditions (0 °C or lower; using ice packs, dry ice, or liquid nitrogen). <CRITICAL> Samples should be kept frozen at all times to avoid metabolic alterations. Thawing of the material for LA-REIMS analysis should be performed at 4-6 °C. <CRITICAL> Upon long-term storage (> 1 year), protein precipitation may occur, for which additional purification measures should be taken prior to LA-REIMS analysis.

- *Saliva samples*: For development of the LA-REIMS procedures as well as to perform rapid fingerprinting in a context of clinical diagnostics, saliva samples were collected from study participants that provided written, informed consent (or parents in case of minors), following approval of the study by the ethics committee. For the examples,

described in this protocol, samples were collected under University Hospital Ghent Ethical Committee (EC 2016/0673).

Collection of saliva should be established under standardized protocols to minimize the impact of confounding factors; *e.g.* with respect to brushing of the teeth, the time slot of sample collection, dietary restrictions with respect to food and drinks consumption prior to sample collection, *etc.* Collection of saliva can be achieved by passive drooling or usage of suitable swabs such as *e.g.* Salivette® synthetic (Sarstedt, Germany) or SalivaBio (SalivaBio, Germany) swabs. After collecting the saliva material in a cryovial, snap-freezing and/or storage at -80 °C is designated. Given the nature of the sample collection, it is possible and advised to collect samples at equipped facilities where these protocols can be applied to minimize metabolic alterations which may occur during *e.g.* sample transport.

To demonstrate the application potential of LA-REIMS saliva fingerprinting in a clinical context, saliva material was collected from children and adolescents (6 to 16 years), which were classified according to weight status, using the IOTF-score (z-score for BMI) (IOTF of 0 for normal weight, 1 for overweight, and 2 for obesity).

<CRITICAL> Fresh samples should be kept frozen at all times to avoid metabolic alterations. Thawing of the material for LA-REIMS analysis should be performed at 4-6 °C.

- *Urine samples:* For development of the LA-REIMS procedures as well as to perform rapid fingerprinting in a context of clinical diagnostics, urine samples were collected from study participants that provided written, informed consent (or parents in case of minors), following approval of the study by the ethics committee. For the examples, described in this protocol, samples were collected under University Hospital Ghent Ethical Committee (EC 2017/1634).

Urine samples can be collected in a plastic 100-mL container in case of adults or children that are neat, whereas alternative tools need to be used in case that children are not neat; *e.g.* Sterisets Newcastle Urine Collection Packs (Sterisets Medical Devices, Portugal). With respect to the latter, urine can be extracted from these packs using a syringe. Samples should be stored as soon as possible at -20 °C (at the participant's home) or -80 °C (at equipped facilities). If transport is needed, this should be realized under cooled conditions (0 °C or lower; using ice packs, dry ice, or liquid nitrogen).

<CRITICAL> It is important that urine is not contaminated with stool material when collecting from children that are not neat. **<CRITICAL>** Samples should be kept frozen at all times to avoid metabolic alterations. Thawing of the material for LA-REIMS analysis should be performed at 4-6 °C.

Sputum: For development of the LA-REIMS procedures, sputum samples were obtained from the Royal Brompton Hospital as part of routine sample collection for monitoring of cystic fibrosis patients. Sputum can be collected as either spontaneous or induced dependent on clinical guidelines and practice in sterile universal containers. Samples can be treated with Sputasol to allow easier handling or analysed neat. They can further be analysed immediately upon sampling or stored at -80 °C. **<CRITICAL>** Samples should be kept frozen at all times to avoid metabolic alterations. Thawing of the material for LA-REIMS analysis should be performed at 4-6 °C. **! Caution** For safety purposes, samples should not be collected from patients with positive results or suspected symptoms of tuberculosis, unless samples can be stored, processed, and analysed in Category III biohazard facilities. If samples contain blood, they should not be analysed and should be disposed of immediately.

- *Human milk*: For development of LA-REIMS procedures, human milk samples were collected from a cohort of breastfeeding dyads with nursing ages ranging between 3 to 24 months. For this purpose, samples were collected under a sub-project (approval number R18006) of the Breastmilk Epigenetic Cohort Study under the Imperial College Healthcare Tissue Bank (HTA licence 12275), which received ethical approval from the Wales Regional Ethics Committee (reference 17/WA/0161). Participants should be free to choose method of expression (hand, electric, or manual pump) but sterility of collection equipment (pump, tubing, containers) should be achieved through steam sterilization following manufacturers' procedures. Samples should be collected into sterile containers suited to the volume of collected human milk sample. Samples can be analysed immediately (within 60 min of collection) or stored at -20 °C or -80 °C depending on availability of facilities. **<CRITICAL>** Samples should be kept frozen at all times to avoid metabolic alterations. Thawing of the material for LA-REIMS analysis should be performed at 4-6 °C.

Reagents

- Isopropylalcohol (LC-MS grade, Sigma Aldrich, cat. no. 34863)
- Ultrapure water (0.055 µS/cm, purchased or obtained from water-purification systems such as Sartorius Arium 661 UV, Sartorius, Germany)
- Sodium formate calibration solution (see 'Reagent set-up' section)
- 0.5 mM sodium hydroxide in 90:10 isopropylalcohol /water (v/v) (Waters, cat. no. 186007052)
- Formic acid > 99.0% (LC-MS grade, Fisher Scientific, Sigma Aldrich, cat. no. 117-50)
- Methanol (LC-MS grade, Sigma Aldrich, cat. no. 646377)

578

579 **External standards (can be added to the isopropylalcohol solvent matrix)**

580 Depending on the experimental set-up, one or multiple compounds may be co-infused with
581 the isopropylalcohol solvent matrix during analysis. Details on how to prepare the solutions
582 are in the section 'Reagent set-up'.

- 583 • (Optional) leucine-enkephalin (Waters, cat. no. 186006013)
- 584 • (Optional) palmitic acid-d₃₁ (Sigma Aldrich, cat. no. 366897)
- 585 • (Optional) 1,2-dimyristoyl-d₅₄-sn-glycero-3-phosphocholine (Sigma Aldrich, cat. no.
586 711047)

587

588 **Equipment**

589 Personalized protective equipment (PPE)

- 590 • Nitril gloves (EcoSHIELD™ Eco NitrilePF 250, NOVOLAB NV, Belgium)
- 591 • Laser Safety Glasses LG16 4.00, 41% Visible Light Transmi Commodity: 9004
592 9010, RoHS: A (compliant 2011/65/EU) (Thorlabs GmbH, Germany)

593 General lab equipment

- 594 • Wipe away® wipes
- 595 • Micropipettes (100-1000 µL, Eppendorf, Germany)
- 596 • Volumetric beakers (VWR, Borosilicate glass 3.3, 100-250-600-1000 mL)
- 597 • Cotton cleaning swabs (Biolab, Hungary, cat. no. CTA90003)
- 598 • Microscope blank glass slides (Marienfeld, Germany, cat. no. 1000000)
- 599 • Microtiter plates (NOVOLAB NV, Belgium, cat. no. 32004)
- 600 • Elmasonic P® ultrasonic bath (Elma, Germany, cat. no. 101 3737)

601 Laser set-up

- 602 • Opolette™ HE2940 pump laser (OPOTEK, LLC, USA) consisting of an Nd:YAG laser,
- 603 • steering optics, optical parametric oscillator (fixed at 2940 nm), wavelength
- 604 separation optics and laser power supply
- 605 • Power meter (Quantel, USA)
- 606 • Aluminium breadboard 200 x 200 x 12.7 mm and M6 Taps (Thorlabs GmbH,
- 607 Germany)
- 608 • Free space optics, enfolding a line of metallic or gold-coated mirrors
- 609 (OptoSigma Global Top, France)
- 610 • Fixed Lens holders LHG RoHS W4148 (Sigma-koki, Japan), kinematic mirror holders
- 611 RoHS W4002 (Sigma-koki, Japan)
- 612 • Pedestal bases (45.8 mm) onto which lenses and mirrors are mounted using pedestal
- 613 clamps RoHS W6039 (Sigma-koki, Japan)
- 614 • Clamps and damped rods for every mirror and/or lens (using a 65x65mm M6
- 615 plateau) (Sigma-koki, Japan)
- 616 • Z Axis Aluminium translation stages (65 x 65 mm) (Sigma-koki, Japan)
- 617 • CAF₂ Plano convex lens RoHS W3189 (Thorlabs GmbH, Germany)
- 618 • PEEK tubing (0.010 in. ID; 30 cm, Thermo Fisher Scientific, USA, cat. no. 10574855)
- 619 • Cytiva PEEK Connectors 1/16 in. Luer (Thermo Fisher Scientific, USA, cat. no.
- 620 11370232)
- 621 REIMS
- 622 • Polytetrafluorethylene tubing (2.5 m, 3.2 mm O.D., 1.6 mm I.D., Sigma Aldrich, cat.
- 623 no.

624 58699) connected to the REIMS interface by means of a T-shaped connector
625 piece (prototype, Waters Research Center, Hungary)

- 626 • REIMS source (prototype, Waters Research Center, Hungary) with a 20 cm inlet
627 capillary of 0.7 mm I.D. mounted onto the housing of the T-shaped connector piece
628 by a length of 0.1 mm I.D. PEEK tubing to a 10 mL syringe
- 629 • 10 mL glass syringe (Hamilton, USA)
- 630 • Harvard 11 Elite syringe pump (Harvard Apparatus, USA) for isopropylalcohol
631 infusion (enclosing external calibration / lock mass compound)
- 632 • Computer (64-bit operating system, 4 GB RAM, Windows 10, Lenovo, China)
- 633 • Xevo G2-XS Quadrupole Time-of-Flight mass spectrometer (Q-TOF-MS) (Waters
634 Corporation, UK)

635

636 **Software**

- 637 1. MassLynxTM (v4.2, Waters)
- 638 2. Progenesis[®] Bridge (v1.0.29, Waters)
- 639 3. Progenesis[®] QI (V2.1, Waters)
- 640 4. SIMCA (v15, Sartorius)

641

642 **Reagent set-up**

643 **Preparation of sodium formate calibration solution**

- 644 1. Prepare 1 mL of 10% formic acid/aqueous solution by mixing 900 µL of ultrapure
645 water and 100 µL LC-MS grade formic acid; sonicate for 5 min (40 kHz, fixed
646 frequency, no heating).

2. Mix 100 μ L of 10% formic acid/aqueous solution to 30 mL of 0.5 mM sodium hydroxide in 90:10 isopropylalcohol/water (v/v) and transfer to an amber glass vial; sonicate for 5 min (40 kHz, fixed frequency, no heating).

■ **PAUSE POINT** The sodium formate solution can be stored at 4 °C for up to 3 months.

(optional) Leucine-enkephalin in isopropylalcohol

Can be used as an external standard for analysis in both positive and negative ionization mode⁷.

1. Add 7.5 mL of ultrapure water to a 3 mg bottle of leucine-enkephalin.
2. Recap, vortex for 30 s at 14 x g and sonicate for 5 min; the resulting 400 ng/ μ L solution can be stored at -20 °C for up to 3 months.
3. Transfer 5 μ L of 400 ng/ μ L leucine-enkephalin solution to a 50 mL glass vial, add 20 mL of isopropylalcohol to obtain a 0.1 ng/ μ L stock solution. Sonicate for 5 minutes (40 kHz, fixed frequency, no heating). Label and store at -20 °C for up to one month.
4. Transfer 1 mL of 0.1 ng/ μ L leucine-enkephalin solution to 9 mL of isopropylalcohol stored in an amber glass vial to obtain a 10 ng/mL solution; sonicate for 5 min (40 kHz, fixed frequency, no heating).

■ **PAUSE POINT** The resulting solution can be used directly in the experiment or stored at -20 °C for up to one week.

(optional) Palmitic acid-d₃₁ in isopropylalcohol

Can be used as external standard for negative ionization only. In case of alternating between positive and negative ionization mode during LA-REIMS analysis, it is possible to add 1,2-

671 dimyristoyl- d_{54} -*sn*-glycero-3-phosphocholine to this solution to also cover positive
672 ionization¹³.

- 673 1. Weigh 1 mg of palmitic acid- d_{31} into a 5 mL glass vial.
 - 674 2. Add 1 mL of ultrapure water, vortex for 30 s at 14 x g and sonicate for 5 min (40
675 kHz, fixed frequency, no heating); the resulting 1 mg/mL stock solution can be
676 stored at -20 °C up to 3 months.
 - 677 3. Transfer 50 μ L of 1 mg/mL stock solution into a 10 mL glass bottle, add 9.95 mL of
678 isopropylalcohol; sonicate for 5 min (40 kHz, fixed frequency, no heating).
- 679 ■ **PAUSE POINT** The resulting 5 ng/ μ L solution can be used for sample analysis or stored
680 at -20 °C for up to one month.

681

682 **(optional) 1,2-dimyristoyl- d_{54} -*sn*-glycero-3-phosphocholine in isopropyl alcohol.**

683 Can be used as external standard for positive ionization only. In case of alternating between
684 positive and negative ionization mode during LA-REIMS analysis, it is possible to add palmitic
685 acid- d_{31} to this solution to also cover negative ionization¹³.

686

- 687 1. Weigh 10 mg of 1,2-dimyristoyl- d_{54} -*sn*-glycero-3-phosphocholine in a 10 mL glass
688 vial.
- 689 2. Add 10 mL of methanol, vortex for 30 s at 14 x g and sonicate for 5 min (40 kHz,
690 fixed frequency, no heating); the resulting 1 mg/mL stock solution can be stored
691 at -20 °C up to 3 months.
- 692 3. Transfer 100 μ L of 1 mg/mL stock solution into a 10 mL glass bottle, add 9.9 mL of
693 isopropylalcohol; sonicate for 5 min (40 kHz, fixed frequency, no heating).

■ **PAUSE POINT** The resulting 100 ng/μL solution can be used for sample analysis or stored at -20 °C for up to one month.

Equipment set-up

MS parameters

Use the following general settings for the Waters Xevo G2-XS QToF instrument.

Instrument parameters	
Mass range, Da	50-1200
Analyser mode	Sensitivity
Data format	Continuum
Acquisition start time, min	0
Acquisition end time, min	0.5 (manual sampling); 0.3 (automated sampling)
Target enhancement	Off

Use the following optimized set-up parameters for the Waters Xevo G2-XS QToF instrument combined with MID-IR laser (Q-switch delay time) or CO₂ laser (laser power and pulse values) for the specified biofluids in positive (+) and negative (-) ion polarity modes. Abbreviations used; NA (not applicable).

	Urine	Feces	Saliva	Plasma	Sputum	Human Milk
Polarity	+ / -	+ / -	+ / -	+ / -	+ / -	+ / -
Solvent flow rate, mL/min	0.30	0.15	0.12 / 0.20	0.30 / 0.20	0.25	0.25
Cone voltage, V	25	40 / 70	20 / 45	30	80	80

Heater bias voltage, V	25	40	75 / 70	40	50	50
Laser wave-length, μm	2.94	2.94	2.94	2.94	10.64	10.64
Laser Q-switch delay time, μs	185	180	165 / 180	170 / 165	NA	NA
Laser power, W	NA	NA	NA	NA	2.0	3.5
Pulse time, ms	NA	NA	NA	NA	40	40
Scan time, s	0.7 / 0.5	0.3	0.5	0.7	1.0	1.0

705

706 Procedure

707 Set-up of the sample holder or container • Timing 1-2 min per sample

- 708 1. Transfer the samples to an appropriate sample holder or container. Sample handling will
709 be different depending on the adopted sampling approach (manual or automated) as
710 well as on the sample matrix (liquid or semi-fluid). For manual sampling of liquids and
711 semi-fluids (A and B) multiple sample slides can be prepared in advance, but preferably
712 not more than 10 samples at a time, as the thin sample layer will dry-out within 20 to 30
713 min under ambient conditions. For automated sampling, the position of the samples
714 within the 96-well plate corresponds to the order within the acquisition sequence (C and
715 D). If more than one well plate is to be analysed, it is recommended to cover the well
716 plates with a self-adhesive polyester foil to reduce sample evaporation pending analysis.

717 A. Manual sampling of liquids

718 Using a 100 μL pipet, transfer 20 to 50 μL of liquid sample (*e.g.* plasma, urine, saliva, human
719 milk, sputum treated with Sputasol) to the glass microscope slide. Use separate slides for

720 each sample.

721 **B. Manual sampling of semi-fluids**

722 Using a disposable sterile spatula, apply a thin layer (approximately 50-80 mg) of semi-fluid
723 sample (*e.g.* feces, untreated sputum) to the microscope slide and distribute evenly.

724 **C. Automated sampling of liquids**

725 Using a 100 µL pipet, transfer 100 µL of liquid sample (*e.g.* plasma, urine, saliva, human milk,
726 sputum treated with Sputasol) to its designated well within a 96-well plate.

727 **D. Automated sampling of semi-fluids**

728 Using a disposable sterile spatula, fill the sample well with semi-fluid sample (*e.g.* feces,
729 untreated sputum) to approximately half of the well's height (80 to 100 mg of sample
730 generally suffices).

731

732 **Set-up of the laser • Timing** 10-15 min

733 2. The authors of this protocol had access to an Nd:YAG MIR OPO laser and CO₂ laser for
734 their experiments. Both lasers have been demonstrated suitable to achieve ablation of
735 liquid and semi-fluid biological material. Preparation of the lasers for sample ablation is
736 detailed in option A and option B, respectively.

737

738 **A. MIR OPO laser**

739 (i) On the front panel of the laser pump power supply, turn the safety key to the 'On'
740 position (45° clockwise).

741 (ii) The LED indicators within the water reservoir level window will light up, ensure that
742 the water level is above the window minimum indication.

(iii) In the system menu of the laser control panel, choose 'system settings' and check the coolant temperature readback. Wait approximately 5 to 10 min until the coolant temperature rises up to 37.5 °C.

(iv) In the Q-switch configuration menu of the laser control panel, set the Q-switch delay time to the optimized value for the selected matrix ('Equipment set-up' section).

(v) In the Q-switch configuration menu, set the Q-switch repetition rate to F/01 (20 Hz).

This value is standard for all described methods independent of the matrix.

B. CO₂ laser

(i) Ensure that the laser hollow core fibre is connected correctly to both the laser unit and the focusing system and that there is no visible damage to the fibre or connecting points.

(ii) Turn on the front panel of the laser and ensure that any connecting gas supplies for cooling are turned on to the correct pressure setting.

(iii) The laser will run through a self-check procedure to ensure it is operating at the appropriate level. Any errors will be communicated on the display screen for user troubleshooting.

(iv) With the laser on 'Standby' mode, adjust the laser operating settings to the required pulsatile mode, pulsatile duration, output power, and gas flow pressure.

(v) On the display screen, switch the laser to 'On' mode and wait 10 s to ensure no system error messages appear.

Connecting REIMS sampling tube, solvent line and MS source • Timing 5-10 min

3. Fix one end of the PTFE transfer tube 1 cm above and 3-4 mm to the side of the laser focus point on the sampling surface (to check the position of the laser focus point, follow steps 2.1 to 2.8. as described in Box 2).
4. Using PEEK fitting ($\frac{1}{4}$ -28 flangeless nuts for $\frac{1}{8}$ " OD tubing), connect the other end of the PTFE transfer tube to the T-piece placed at the end of the ion transfer capillary in the REIMS source (Fig. 4b).
5. Fill the 10 mL glass Luer-lock syringe with isopropylalcohol (for isopropylalcohol containing reference external standards follow 'Reagent set-up' section).
6. Use Cytiva Luer PEEK Connectors to connect the syringe to the PEEK tubing; use two-piece PEEK fittings with ferrules to connect the solvent line with the T-piece at the level of the MS source (Fig. 4b).

System preparation and optimization • Timing 20-25 min

7. On the front panel of the solvent pump, set the solvent flow rate according to the optimized method parameters per sample matrix and chosen polarity ('Equipment set-up' section), and turn on the flow by pressing the 'Run' button.
8. Observe the MS signal from the solvent flow on the MassLynxTM tune page. Record the blank solvent signal and compare the spectrum profile with the blank solvent signal from a previous experiment.

? TROUBLESHOOTING

9. (Optional) If using external standards within the isopropylalcohol solution, check if the *m/z*-peaks of these external standards are clearly visible within the solvent spectrum on the MassLynxTM tune page.

10. Follow the procedure described in the 'Sample analysis' section (step 30 A and B), analyse 10 eQC samples, respectively, in negative and positive ion mode. This additional measure will ensure conditioning of the instrument with the matrix-specific ions and reduce MS signal variation over time during subsequent analysis of biological samples.

External calibration of the REIMS • Timing 40 min

▲ **CRITICAL STEP** The instrument should be calibrated daily to ensure high mass accuracy.

11. Fill the glass syringe (10 mL Fixed Luer Lock Tip Syringe, SGE, cat. no. 008970) with 0.5 mM sodium formate calibration solution.

12. Initiate MS scanning by pressing the 'On' ('I') button on the MassLynx™ tune page.

13. On the front panel of the solvent pump, set up the solvent flow rate at 0.2 mL/min and initiate the flow by pressing the 'Run' button.

14. Wait until the sodium formate spectrum is visible and stable on the MassLynx™ tune page (multiple high peaks distributed across entire m/z -range).

15. Select the 'MS console' tab in the MassLynx™ tune page and subsequently the 'IntelliStart' tab. Set the system to 'Configuration mode' by choosing it in the 'Configure' drop-down menu at the top of the page.

16. Tick the empty box next to the 'Create Calibration' option on the instrument configuration panel and press 'Start'.

17. The step-by-step create calibration wizard algorithm will appear on the screen. Press 'Create Profile Editor...', then select 'File' drop-down from the pop-up window and press 'New' to define a new calibration profile.

18. Populate the 'New calibration profile window' by defining the profile name, setting the mass range from 50 to 1200 Da and the calibration type as 'Assisted'.

19. In the calibration profile window click 'Edit...' next to the 'Positive polarity' section. In the new window choose 'Enabled' as an option for calibration reference compound and select sodium formate in the drop-down menu.
20. Repeat step 15 for the 'Negative polarity' section within the calibration profile window.
- **PAUSE POINT** Once created, the calibration profile can be updated each time a new instrument calibration is performed by resetting the already calibrated profile through the 'Edit' drop-down menu in the Calibration profile editor. The reset profile will save all defined calibration settings but lacks calibration data, so it can be used for new calibration (the 'green tick' next to the calibration profile will change to 'orange triangle' in the Calibration Profile pull down menu).
21. Choose both sensitivity and resolution mode for positive and negative polarity calibration by ticking the corresponding boxes in the Calibration set-up wizard page.
22. Check both boxes ('Display Report' and 'Make Calibration Profile Active') in the 'Options' section.
23. Do not change any settings on the other pages of the Create Calibration wizard sequence and click the 'Next' button on the bottom of every page to reach the end of the sequence.
24. Press the 'Start' button at the end of the Create Calibration wizard sequence. The calibration process will be initiated by the software.
25. At the end of the calibration process, the Calibration report for evaluation pops up. All peaks in the acquired datafile should be matched with the reference file for sodium formate (100% peaks detected), the RMS residual mass and 95% confidence band should be below 5 ppm mass deviation.

26. If the abovementioned criteria for good system calibration are met, accept the calibration report by clicking on the green 'tick' symbol above on the Calibration report page. Continue the evaluation for both modes (sensitivity and resolution) and both polarities (negative and positive).

27. When calibration has been successfully finalized, a new calibration file will be automatically saved and uploaded on the MS control panel.

28. Remove the remaining calibration solution from the syringe and replace the solvent to isopropylalcohol, start the solvent pump and initiate the MS acquisition. Flush approximately 20 min to remove the remaining calibration solution from the system.

29. After approximately 20 min, check the tune page MS spectrum; no additional peaks aside from the isopropylalcohol ions should be present within the spectrum TIC.

Sample analysis

30. Depending on whether a manual or automated sampling analysis will be performed, follow the steps in options A or B.

A. Manual analysis • Timing 30 s/sample (per ionization mode)

(i) In the MassLynxTM software window, initiate MS acquisition by selecting all samples in the sample sequence that should be analysed within one batch and press the 'Run sequence' button on top of the page.

(ii) Activate the laser by pressing the 'Start' button next to the flash lamp and Q-switch indicators on the laser control panel.

(iii) Place the microscope slide, carrying the sample, under the laser focus point for ablation; remove after 3 s.

858 (iv) (Optional) Repeat step (iii) to generate several replicates. If you do this,
859 record 3 to 4 s (blank background signal) between burns for optimal peak
860 resolution.

861 (v) Repeat steps (i) to (iv) for any other sample to be analysed.

862 ▲ **CRITICAL STEP** Routinely clean the laser focusing lens from the side of ablation with a
863 cotton bud dipped in ethanol every 5 to 10 burns depending on the normal rate of
864 contamination. Clean the focusing lens in a similar fashion whenever the intensity of
865 acquired spectra decreases with more than 10%.

866 (vi) (Optional) Repeat steps (i) to (v) for all samples when analysing the samples in
867 the opposite polarity mode, changing to the appropriate experimental
868 settings ('Equipment set-up' section).

869 **B. Automated analysis • Timing** 23 s/sample (per ionization mode)

870 (i) Position the microtiter plate(s), containing the samples, on the sampling
871 surface.

872 (ii) Ensure that the laser focus point lies in the middle of the first well (check with
873 the alignment diode beam, see Steps 1-8 for external optics alignment
874 verification as described in Box 2).

875 (iii) Within the laser controlling software, the following experimental sequence
876 should be programmed: a 3-s burn followed by a 20.6-s cooldown period.

877 (iv) Within the stage controlling software, define the number of sample-filled
878 wells to be analysed (*i.e.* the number of repetitive movements that the stage
879 has to perform to position every sample-filled well under the laser focus
880 point). The moving stage 'move and wait' cycle timing should correspond to
881 the laser sequence program cycle of 23.6 s).

- 882 (v) Initiate the autosampler robot sequence.
- 883 (vi) After 5 s initiate the MS instrument acquisition sequence. This will set the
- 884 burn 'retention time' at approximately 15 s in the acquisition file.
- 885 ▲ **CRITICAL STEP** Clean the laser focusing lens from the side of ablation with a cotton bud
- 886 dipped in ethanol every 10 to 15 burns.
- 887 (vii) (Optional) Repeat steps (iv)-(vii) for all samples when analysing the samples in
- 888 the opposite polarity mode, changing to appropriate experimental settings
- 889 ('Equipment set-up' section).

890

891 **Computational analysis • Timing 1 h/500 samples**

892 31. Load the acquired spectra into the appropriate software.

893 ▲ **CRITICAL STEP** Data collected on the LA-REIMS instrument (Waters) are processed

894 sequentially by Progenesis[®] Bridge (v1.0.29, Waters) and Progenesis[®] QI (V2.1,

895 Waters); see Box 3 Steps 1-11.

896 32. Apply pre-processing to the spectra, including noise removal, baseline subtraction,

897 selecting burns and peak picking.

898 33. Load the peak lists (*m/z*-features) into the appropriate software.

899 ▲ **CRITICAL STEP** The choice of software will depend on the classification modelling

900 approach selected (commercial, open-source software) and compatibility with the

901 output format after pre-processing. Here, data collected from Progenesis[®] QI (v2.1,

902 Waters) are loaded into SIMCA (v15, Sartorius); see Box 3 Steps 12-22.

903 34. Select features that show statistical and significant differences in the discriminative

904 analysis.

905

Cleaning and maintenance procedures • Timing 1.5 h

35. After the experiment, and as part of troubleshooting, you will need to clean and maintain the instruments. Follow the guidelines in Table 1 for maintenance methods and frequency rate for each hardware component of the LA-REIMS set-up.

Table 1 Cleaning and maintenance			
Component	Method	Frequency	Considerations
Beam transmission (mirror or fibre)	Clean the mirror with manufacturer recommended solvent and the fibres by flushing with nitrogen or helium	As necessary based on laser power output monitoring.	Replacement of fibre should be in line with manufacturer recommendations or as necessary based on laser power output monitoring.
Beam focusing lens	Clean with manufacturer recommended solvent, absorbed into non-scratch material swab/tissue.	Daily or as necessary based on laser power output monitoring.	Analysis of samples such as feces may result in debris build-up on lens and requires more frequent cleaning.
Aerosol transfer line	It is difficult to remove solvent from the line, so if it is dirty, the dirty section	Trimming of 2 cm from the ends is recommended daily	

	should be removed. First trim 2 cm from the ends, and if this does not improve things, replace the PTFE tubing in its entirety.	with replacement of entire length weekly.	
T-piece and inlet capillary	Dismantle the set-up and sonicate (40 kHz, 'Sweep' mode/alterating frequency, no heating) in isopropylalcohol/water (50:50 v/v) for 10 min followed by air drying for 30 min.	Daily.	Cleaning solvent may be altered to remove particular chemical contamination (<i>e.g.</i> MS Cleaning Solution (Waters, cat. no. 186006846) or appropriate mild soap solution for precipitated proteins).
REIMS interface	Dismantle the interface and swab the exposed parts using methanol using non-scratch material swab/tissue followed by	Weekly or as necessary if contamination is detected in background signal.	If venting of the instrument and recalibration is required, this should be accommodated in

	air drying for 30 min.		the analytical schedule.
Ion guide (<i>e.g.</i> Waters StepWave)	Remove the ion guide from the instrument housing and clean using manufacturer recommended routine. Typically, 30 min sonication (40kHz, 'Sweep' mode/alterating frequency, no heating) in MS Cleaning Solution (Waters, cat. no. 186006846), 10 min sonication in methanol:water (50:50 v/v) followed by 10 min sonication in methanol and air drying for 30 min.	Weekly or as necessary if contamination is detected in background signal.	As venting is required, clean the ion guide at the same time that you clean the REIMS interface.

911

912 Troubleshooting

913 Troubleshooting advice can be found in Table 2.

914

Table 2 Troubleshooting table			
Step	Problem	Possible reason	Solution
Box 2, step 5	While aligning the laser beam, the green light is not visible within the alignment target.	Laser energy output is not sufficient to activate fluorescent photosensitive matrix on alignment target surface.	Decrease the laser Q-switch delay to 300 μ s.
Box 3, step 1c	The number of bridged files is different than the number of burns.	When less bridged files than burns are observed, the TIC threshold may be set too high (only highest peaks are recognized). In case only one bridged file is produced after processing, this might imply that the TIC threshold is either too low and all signals above the threshold	Check peak and background intensities in 10% of samples. Make sure to include runs at the end of the experiment as intensities might be somewhat lower. If possible – choose one threshold value for processing of all experimental files

are combined in one peak or too high and only the highest peak is detected. In the latter case, often samples for which none of the peaks meet this high threshold value will be absent from the 'processed' directory.

within one polarity mode. If the differences in intensities within the experiment are too large to correctly process all files with one TIC threshold (may be noticeable for 100 and more samples) consider dividing files into batches.

NOTE: signal intensities differ substantially between polarities within one experiment. Therefore positive and negative data should be processed

			separately with separate TIC threshold values.
Box 3, Step 15c	The errors 'no valid values', 'missing observation ID' or 'missing variable ID' pop up.	No values present in the dataset.	Check if all '#DIV/0!', 'NA', '∞', ... values are removed from the dataset, including the header information.
Step 8	While infusing pure isopropylalcohol, the tune page spectrum displays additional <i>m/z</i> signals.	Source, solvent line or sample tube may be contaminated.	Perform additional cleaning and/or change infusion solvent.

915

916 **Timing**

917 Step 1, Set-up of the sample holder or recipient: 1-2 min/sample

918 Step 2, Set-up of the laser: 10-15 min
919 Steps 3-6, Connecting REIMS sampling tube, solvent line and MS source: 5-10 min
920 Steps 7-10, System preparation and optimization: 20-25 min
921 Steps 11-29, External calibration of the REIMS interface: 40 min
922 Step 30A, Manual analysis: 30 s/sample
923 Step 30B, Automated analysis: 23 s/sample
924 Steps 31-34, Computational analysis: 1 h/500 samples
925 Step 35, Cleaning and maintenance: 1.5 h
926 Box 1, Sample preparation: 0-15 min/sample
927 Box 2, Laser alignment verification: 20-30 min
928 Box 3, LA-REIMS data analysis & classification modelling: 1 h/500 samples

929

930 **Anticipated results**

931 With this protocol, we provide guidelines to perform rapid LA-REIMS metabolic
932 fingerprinting of various human biofluids, *i.e.* saliva, urine, plasma, stool, sputum, and milk.
933 Hereby, aspects on both sample handling and instrumental set-up are detailed. Using the
934 outlined procedures, high-quality data for a broad m/z -spectrum (50 – 1200 Da) can typically
935 be acquired in less than 1 min per sample; including sample loading and inter-sample
936 equilibration. No significant pre-treatments of the biofluids are needed, with the exception
937 of saliva. As such, LA-REIMS offers relevant potential for diverse clinical applications, in
938 which rapid discriminative metabotyping and/or (point-of-care) personalized health care
939 provision are major objectives. In this section, we discuss the anticipated results as may be
940 obtained upon biofluid LA-REIMS analysis, with specific elaborations on the generated
941 molecular fingerprints, the precision of the analysis, and the application potential in a clinical

context. For this, we chose feces as a semi-fluid and saliva as a real biofluid, as examples for in-depth illustration of some particular aspects.

Molecular fingerprints

For all biofluids and semi-fluids, the mass spectra that are generated by LA-REIMS comprise several hundreds of features across the 50 – 1200 Da m/z scan range, for both negative and positive ionization mode. In Fig. 5, we show representative molecular fingerprints for saliva, plasma, urine, stool, milk, and sputum, as obtained from a single burn of a pooled sample ($n = 10$).

We did a similar experiment where we analysed the samples by DIMS and have included the methods and results for this in the Supplementary Discussion. From these results it was clear that we were able to get a higher metabolome coverages using LA-REIMS. There was also substantial contamination at the ionization source for DIMS making robust analysis of large sample batches problematic. While these problems can be overcome using appropriate sample pre-treatment for direct infusion MS of biofluids (*e.g.* saliva, urine, blood) and even essential for semi-fluids (*e.g.* feces), this requirement detracts from the pursuit of rapid (real-time) fingerprinting, as is achieved by LA-REIMS.

For the various matrices, the total number of unique features that could be retrieved by considering the samples from ten individuals was 3628 for saliva (52.0% of these were detected in negative ionization mode), 3015 for plasma (47.2% in negative), 3767 for urine (54.1% in negative), 2078 for feces (65.9% in negative), 3065 for milk (31.6% in negative), and 2039 for sputum (35.1% in negative).

In-depth analysis of the metabolic fingerprints shows that the lower m/z -region of 50 – 400 Da generally contributes the most to the achieved metabolome coverage (number of

detected features) for negative ionization mode, but the m/z region of 200 – 600 Da contributes the most for positive ionization mode (Fig. 6). This most likely relates to the specific metabolome composition of the assessed matrices and the number of metabolite representatives for the various chemical classes (*i.e.*, reflected by various functional groups and associated ionization behaviours). Also UHPLC-HRMS analysis revealed specific m/z -patterns, corresponding to the ionization mode, as *e.g.* illustrated for saliva by Wijnant *et al.* (2020)¹³.

Taking into account the absolute metabolome coverage per matrix and making the comparison between matrices, it may be noted that the metabolome of feces and milk contain a relatively low proportion of high-weight features (> 800 Da), whereas the sputum metabolome encompass a relatively low proportion of low-weight features (< 200 Da). It has indeed been described that sputum especially contains a high fraction of various lipid species, including highly abundant sphingolipids such as sphingomyelins, ceramides, and lactosylceramides⁴³. In human milk, a high abundance of various low- to medium-weight metabolites have been reported, such as oligosaccharides, amino acids and derivatives, and fatty acids and associated metabolites⁴⁴. For feces, the defined metabolome composition may largely be determined by the metabolic activity of the gut microbial community, including the metabolization of large and complex structures⁴⁵.

The above-mentioned data were obtained for each biofluid based on a single burn. A typical burn for positive and negative ionization is presented in Fig. 3. Taking into account the scan time (see ‘Equipment set-up’ section), the total number of scans acquired per burn varied between 4.2 scans (plasma) and 10.0 scans (feces). A higher background level was generally

obtained in positive ionization mode⁷ for all matrices, as displayed for feces (Fig. 3). It was verified that especially *m/z*-features < 350 Da contributed to this background signal.

Precision

As a major parameter to assess the performance quality, the precision of the LA-REIMS method was verified for feces as a semi-fluid representative and saliva as a real biofluid. Repeatability was evaluated based on the repetitive (n = 3) laser ablation of a single sample as well as the sequential analysis of ten different samples from the same sample pool. Reproducibility was assessed for three consecutive analysis days whereby ten sample aliquots were analysed per day, prepared from the same sample pool, stored at -80 °C, and all subjected to one freeze-thaw cycle.

For the repeatability that was assessed by subjecting a single sample to three consecutive ablation events, it was observed that the achieved metabolome coverage was highly repeatable across the various burns and this for both ionization modes and matrices (Table 3, minimum of 84.5% congruence). With respect to the total ion current (TIC), it was noted that significant differences may occur from burn to burn (Table 3, CV% up to 45.5%). This is evidence that TIC-based data normalization is essential to attain high-quality LA-REIMS metabolomics datasets. Indeed, by applying TIC-based normalization, high signal repeatability was calculated with $\geq 92.5\%$ of the features found in feces having a $CV \leq 30\%$ ⁴⁶; the corresponding value for saliva was $\geq 80.9\%$. Based on the achieved metabolome coverages that were highly similar across burns and the high signal repeatability upon TIC-based normalization, acquisition of representative LA-REIMS metabolic fingerprints is possible based on one burn only.

Table 3 | Evaluation of the short-term reproducibility, based on repetitive laser ablation (n = 3) of a single sample. Abbreviations used; CV (coefficient of variance), TIC (total ion current).

	Unique features within each burn (%)			Average TIC $\pm$ CV% across burns	Percentage of features with CV% $\leq 30\%$
	1 st burn	2 nd burn	3 rd burn		
<i>Feces</i>					
Positive ionization	9.4	4.1	6.1	$7.8e^7 \pm 28.1$	92.5
Negative ionization	3.7	0.4	4.3	$3.8e^8 \pm 45.4$	96.4
Merged polarities	5.4	1.6	4.8		95.5
<i>Saliva</i>					
Positive ionization	2.6	1.7	1.5	$3.6e^8 \pm 7.7$	83.4
Negative ionization	0.5	0.2	1.3	$1.9e^8 \pm 45.5$	80.9
Merged polarities	1.5	0.9	1.4		82.0

1015

1016 Evaluation of the intra-day repeatability for the ten consecutive sample analyses was

1017 achieved by assessing the similarity of the molecular profiles in terms of metabolome

1018 coverage and by calculating the CV% for the TIC-normalized feature abundances. For feces

1019 and saliva, metabolome coverage was considered highly repeatable in terms of number of
 1020 features detected (Table 4). Moreover, the CV% as determined for the TIC-normalized
 1021 features' abundances indicated that 71.8% of the fecal features and 88.9% of the salivary
 1022 features meet the 30% CV-threshold, typically used in metabolomics analysis⁴⁶. Inter-day
 1023 repeatability (*i.e.* the reproducibility) results were generally quite similar to those obtained
 1024 for the intra-day repeatability assessment, indicating that high-quality data acquisition by
 1025 LA-REIMS can be actualized for both biofluid and semi-fluid analysis over the course of
 1026 several days (Table 4). Hereby, internal QC-samples can be used as an efficient strategy to
 1027 adjust for possible instrumental variation (LOESS-based normalization).

1028 It should be noted, however, that for feces in positive ionization mode, only 38.9% of the
 1029 detected features had an acceptable $CV \leq 30\%$. This may partially relate to the fact that a
 1030 higher noise level is observed in positive ionization mode, which may somewhat hamper
 1031 reproducible analysis. In addition, microbial enzymatic activity may reactivate after preparing
 1032 the fecal slurry, as a result of which the metabolic composition of the pooled sample may be
 1033 altered.

1034

Table 4 | Evaluation of the short-term repeatability (10 samples, intra-day) and long-term reproducibility (3 days, every day 10 samples). Abbreviations used; CV (coefficient of variance).

	Short-term repeatability			Long-term reproducibility		
	(10 samples)			(3 days, 10 samples per day)		
	Average	Percentage	of	Average	Percentage	of
	number of	features with CV		number of	features with	

	features $\pm$ CV%	$\leq 30\%$	features $\pm$ CV%	CV $\leq 30\%$
<i>Feces</i>				
Positive ionization	546 $\pm$ 3.8	67.9	528 $\pm$ 6.5	38.9
Negative ionization	1217 $\pm$ 3.0	73.5	1193 $\pm$ 3.8	70.3
Merged polarities	1765 $\pm$ 2.2	71.8	1721 $\pm$ 3.4	66.6
<i>Saliva</i>				
Positive ionization	1079 $\pm$ 3.2	82.6	1090 $\pm$ 2.4	78.8
Negative ionization	1278 $\pm$ 0.5	94.3	1178 $\pm$ 0.4	88.7
Merged polarities	2357 $\pm$ 1.4	88.9	2284 $\pm$ 2.3	82.6

1035

1036 **Classification model**

1037 To demonstrate the application potential of LA-REIMS for rapid fingerprinting of bio/semi-
1038 fluids and to substantiate the robustness of the methodology, this section describes two
1039 example clinical cases, *i.e.* type 2 diabetes and overweight/obesity. For these cases, LA-
1040 REIMS discriminative fingerprinting according to health status was pursued by considering,
1041 respectively, a semi-fluid (feces) and real biofluid (saliva).

1042

Based on the fecal LA-REIMS fingerprints, a valid two-class OPLS-DA model was established to discriminate between individuals with type 2 diabetes and those with normal glycaemic state (*i.e.* euglycemia). Also, the PCA-X score plot (Fig. 7) showed some segregation of samples according to health status. The OPLS-DA model (Fig. 7) was validated with a CV-ANOVA p-value of 1.93e^{-17} , valid permutation testing, and $R^2(\text{X})$ of 0.230, $R^2(\text{Y})$ of 0.946 and $Q^2(\text{Y})$ of 0.734. Moreover, using a five-fold 20%-leave out validation strategy, a general classification accuracy of 90.5% was calculated, with a type 2 diabetes sensitivity of 89.5% and specificity of 91.7%. Initial classification of individuals according to glycaemic state was based on the glycated haemoglobin concentration (HbA1c), thereby implementing a 60 mmol/mol threshold criterion. A total of 72 individuals took part in the study, whereby 36 individuals had been assigned a state of type 2 diabetes and 36 individuals a state of euglycemia. A detailed explanation on the sample collection, data analysis, data processing and interpretation of the results can be consulted in Van Meulebroek *et al.* (2020)¹². Whereas the main purpose of this experiment was the rapid discrimination and thus diagnosis of glycaemic state based on rapid LA-REIMS metabolic fingerprinting of the semi-fluid feces, the instrumental platform also allows for some more in-depth interpretation of discriminative metabolites (*i.e.* potential markers). To this end, samples can be subjected to MS/MS fragmentation, which offers possibilities for tentative identification. In our study, this fragmentation strategy allowed to assign relevant metabolite identities, substantiating the method also suited for exploration of the mechanisms involved in pathophysiology. Amongst others, 6-hydroxymelatonin, several nicotinamides, D-glucose, biotripyrrin, and homocysteine-associated metabolites were tentatively identified as metabolite markers. As such, applying LA-REIMS fingerprinting, classification according to glycaemic state was

considered possible based on validated supervised modelling, biological qualification of tentatively identified metabolite markers, and supportive data from UHPLC-HRMS analysis¹².

To assess overweight and obesity in young adolescents (6 to 16 years), saliva samples from 35 individuals with a healthy weight and 35 individuals with overweight/obesity were collected and subjected to LA-REIMS analysis. Hereby, the primary purpose was to achieve discrimination according to weight status, as this may enclose interesting opportunities to appoint metabolic perturbations according to pathophysiological state and evaluate *e.g.* the contribution of etiological factors and treatment efficacy. Initial adiposity classifications were based on BMI z-scores (adjusted BMI for age and sex), following Roelants *et al.* (2009)⁴⁷ and extended international (IOTF) body mass index cut-offs for thinness, overweight, and obesity by Cole *et al.* (2012)⁴⁸. A valid two-class OPLS-DA model (Fig. 7) could be established, which allowed for discrimination between healthy weight (IOTF of 0) and overweight/obesity (IOTF ≥ 1). Validation parameters comprised a CV-ANOVA *p*-value of 9.01×10^{-21} , valid permutation testing, and an $R^2(X)$ of 0.227, $R^2(Y)$ of 0.946, and Q^2 of 0.808. In addition, based on a five-fold 20%-leave out validation strategy, a general classification accuracy of 97.1% was achieved, with a sensitivity of 100% and specificity of 94.3%. A detailed explanation on the sample collection, data analysis, data processing and interpretation of the results can be consulted in Wijnant *et al.* (2020)¹³.

Reporting summary: Further information on research design is available in Nature Research Reporting Summary linked to this article.

Data availability

Datasets relevant to our published supporting primary papers can be made available from the corresponding author upon reasonable request. The source data for figures is publicly available at Figshare repository:

Fig. 3 <https://doi.org/10.6084/m9.figshare.14258423.v1>;

Fig. 5 <https://doi.org/10.6084/m9.figshare.14258438.v1>;

Fig. 6 <https://doi.org/10.6084/m9.figshare.14258459.v2>

References:

1. Gong, Z., Zhang, J. & Xu, Y.-J. Metabolomics Reveals that *Momordica charantia* Attenuates Metabolic Changes in Experimental Obesity. *Phyther. Res.* **31**, 296–302 (2017).
2. Pham-Tuan, H., Kaskavelis, L., Daykin, C. A. & Janssen, H. G. Method development in high-performance liquid chromatography for high-throughput profiling and metabonomic studies of biofluid samples. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **789**, 283–301 (2003).
3. Wishart, D. S. Metabolomics for investigating physiological and pathophysiological processes. *Physiol. Rev.* **99**, 1819–1875 (2019).
4. Wijnant, K. *et al.* Validated Ultra-High-Performance Liquid Chromatography Hybrid High-Resolution Mass Spectrometry and Laser-Assisted Rapid Evaporative Ionization Mass Spectrometry for Salivary Metabolomics. *Anal. Chem.* **92**, 5116–5124 (2020).
5. Johnson, C. H., Ivanisevic, J. & Siuzdak, G. Metabolomics: Beyond biomarkers and towards mechanisms. *Nat. Rev. Mol. Cell Biol.* **17**, 451–459 (2016).

- 1114 6. Ferreira, C. R. *et al.* Ambient ionization mass spectrometry for point-of-care
1115 diagnostics and other clinical measurements. *Clin Chem.* **62**, 99–110 (2016).
- 1116 7. Cameron, S. J. S. *et al.* Evaluation of Direct from Sample Metabolomics of Human
1117 Feces Using Rapid Evaporative Ionization Mass Spectrometry. *Anal. Chem.* **91**, 13448–
1118 13457 (2019).
- 1119 8. Ogrinc, N. *et al.* Water-assisted laser desorption/ionization mass spectrometry for
1120 minimally invasive in vivo and real-time surface analysis using SpiderMass. *Nat.*
1121 *Protoc.* **14**, 3162–3182 (2019).
- 1122 9. Schäfer, K. C. *et al.* In vivo, in situ tissue analysis using rapid evaporative ionization
1123 mass spectrometry. *Angew. Chemie - Int. Ed.* **48**, 8240–8242 (2009).
- 1124 10. Clendinen, C. S., Monge, M. E. & Fernández, F. M. Ambient mass spectrometry in
1125 metabolomics. *Analyst* **142**, 3101–3117 (2017).
- 1126 11. Li, L., Hsieh, H. & Hsu, C. Clinical Application of Ambient Ionization. *Mass spectrometry*
1127 *(Tokyo)* **6**, Spec Iss S0060 (2017).
- 1128 12. Van Meulebroek, L. *et al.* Rapid LA-REIMS and comprehensive UHPLC-HRMS for
1129 metabolic phenotyping of feces. *Talanta* **217**, 121043 (2020).
- 1130 13. Wijnant, K. *et al.* Validated Ultra-High-Performance Liquid Chromatography Hybrid
1131 High- Resolution Mass Spectrometry and Laser-Assisted Rapid Evaporative Ionization
1132 Mass Spectrometry for Salivary Metabolomics. *Anal. Chem.* **92**, 5116–5124 (2020).
- 1133 14. Fatou, B. *et al.* In vivo Real-Time Mass Spectrometry for Guided Surgery Application.
1134 *Sci. Rep.* **6**, 1–14 (2016).
- 1135 15. Kuo, T. H., Dutkiewicz, E. P., Pei, J. & Hsu, C. C. Ambient Ionization Mass Spectrometry
1136 Today and Tomorrow: Embracing Challenges and Opportunities. *Anal. Chem.* **92**,
1137 2353–2363 (2020).

- 1138 16. Sächfer, K.-C. *et al.* In situ, real-time identification of biological tissues by ultraviolet
1139 and infrared laser desorption ionization mass spectrometry. and infrared laser
1140 desorption ionization mass spectrometry. *Anal. Chem.* **83**, 1632-1640 (2011).
- 1141 17. Balog, J. *et al.* Intraoperative Tissue Identification Using Rapid Evaporative Ionization
1142 Mass Spectrometry. *Sci. Transl. Med.* **5**, 1–11 (2013).
- 1143 18. Feider, C. L., Krieger, A., Dehoog, R. J. & Eberlin, L. S. Ambient Ionization Mass
1144 Spectrometry: Recent Developments and Applications. *Anal Chem.* **91**, 4266–4290
1145 (2019).
- 1146 19. Fillet, M. & Fre, M. Metabolomics in Medicinal Chemistry The emergence of
1147 metabolomics as a key discipline in the drug discovery process. *Drug Discovery Today*
1148 *Technol.* **13**, 19–24 (2015).
- 1149 20. Golf, O. *et al.* Rapid evaporative ionization mass spectrometry imaging platform for
1150 direct mapping from bulk tissue and bacterial growth media. *Anal. Chem.* **87**, 2527–
1151 2534 (2015).
- 1152 21. Clendinen, C. S., Monge, M. E. & Fernández, F. M. Ambient mass spectrometry in
1153 metabolomics. *Analyst* **142**, 3101–3117 (2017).
- 1154 22. Nemes, P. & Vertes, A. Ambient mass spectrometry for in vivo local analysis and in situ
1155 molecular tissue imaging. *TrAC - Trends Anal. Chem.* **34**, 22–34 (2012).
- 1156 23. Li, H., Balan, P. & Vertes, A. Molecular Imaging of Growth , Metabolism , and
1157 Antibiotic Inhibition in Bacterial Colonies by Laser Ablation Electrospray Ionization
1158 Mass Spectrometry. *Angew Chem Int Ed Engl.* **55**, 15035-15039 (2016).
- 1159 24. Suva, M. A Brief Review on Dried Blood Spots Applications in Drug Development. *J.*
1160 *Pharm. Biosci.* **2**, 17–23 (2014).
- 1161 25. Van Meulebroek, L. *et al.* Holistic Lipidomics of the Human Gut Phenotype Using

- Validated Ultra-High-Performance Liquid Chromatography Coupled to Hybrid Orbitrap Mass Spectrometry. *Anal. Chem.* **22**, 12502–12510 (2017).
26. De Paepe, E. *et al.* A validated multi-matrix platform for metabolomic fingerprinting of human urine, feces and plasma using ultra-high performance liquid-chromatography coupled to hybrid orbitrap high-resolution mass spectrometry. *Anal. Chim. Acta* **1033**, 108–118 (2018).
27. Cameron, S. J. S. & Takáts, Z. Mass spectrometry approaches to metabolic profiling of microbial communities within the human gastrointestinal tract. *Methods (San Diego, Calif.)* **149**, 13–24 (2018).
28. Gowers, G. O. F. *et al.* Off-Colony Screening of Biosynthetic Libraries by Rapid Laser-Enabled Mass Spectrometry. *ACS synthetic biology* **8**, 2566–2575 (2019).
29. Williams, J. P. & Scrivens, J. H. Coupling desorption electrospray ionisation and neutral desorption/extractive electrospray ionisation with a travelling-wave based ion mobility mass spectrometer for the analysis of drugs. *Rapid Commun. Mass Spectrom.* **22**, 187–196 (2008).
30. Jones, E. A. *et al.* Matrix assisted rapid evaporative ionization mass spectrometry. *Anal. Chem.* **91**, 9784-9791 (2019).
31. De Spiegeleer, M. *et al.* Impact of storage conditions on the human stool metabolome and lipidome: Preserving the most accurate fingerprint. *Anal. Chim. Acta* **1108**, 79-88 (2020).
32. Laparre, J. *et al.* Impact of storage conditions on the urinary metabolomics fingerprint. *Anal. Chim. Acta* **951**, 99-107 (2017).
33. Cheng, K., Brunius, C., Fristedt, R. & Landberg, R. An LC-QToF MS based method for untargeted metabolomics of human fecal samples. *Metabolomics* **16**, 46 (2020).

- 1186 34. Zheng, J., Dixon, R.A . & Li, L. Development of isotope labeling LC-MS for human
1187 salivary metabolomics and application to profiling metabolome changes associated
1188 with mild cognitive impairment. *Anal. Chem.* **84**, 10802-10811 (2012).
- 1189 35. Pinto, J. *et al.* Human plasma stability during handling and storage: impact on NMR
1190 metabolomics. *Analyst* **139**, 1168-1177 (2014).
- 1191 36. Laparre, J. *et al.* Impact of storage conditions on the urinary metabolomics fingerprint.
1192 *Anal. Chim. Acta* **951**, 99-107 (2017).
- 1193 37. Berkow, S. E. *et al.* Lipases and lipids in human milk: effect of freeze-thawing and
1194 storage. *Pediatr. Res.* **18**, 1257-1262 (1984).
- 1195 38. Zhao, J. , Evans, C. R., Carmody, L. A. & LiPuma, J. J. Impact of storage conditions on
1196 metabolite profiles of sputum samples from persons with cystic fibriosis. *J. Cyst.*
1197 *Fibros.* **14**, 468-473 (2015).
- 1198 39. Smith, C. A., Want, E. J., O'Maille, G., Abagyan, R. & Siuzdak, G. XCMS: Processing
1199 mass spectrometry data for metabolite profiling using nonlinear peak alignment,
1200 matching, and identification. *Anal. Chem.* **78**, 779–787 (2006).
- 1201 40. Pluskal, T. T., Castillo, S., Villar-Briones, A., Oresic, M. & Orešič, M. MZmine 2: modular
1202 framework for processing, visualizing, and analyzing mass spectrometry-based
1203 molecular profile data. *BMC Bioinformatics* **11**, 395 (2010).
- 1204 41. Abdi, H. Partial least squares regression and projection on latent structure regression.
1205 *Wiley Interdiscip. Rev. Comput. Stat.* **2**, 97–106 (2010).
- 1206 42. Bylesjö, M. *et al.* OPLS discriminant analysis: combining the strengths of PLS-DA and
1207 SIMCA classification. *J. Chemom.* **20**, 341–351 (2006).
- 1208 43. Quinn, R. A. *et al.* Microbial, host and xenobiotic diversity in the cystic fibriosis sputum
1209 metabolome. *ISME J.* **10**, 1483-1498 (2016).

44. Smilowitz, J.T. *et al.* The human milk metabolome reveals diverse oligosaccharide profiles. *J. Nutr.* **143**, 1709-1718 (2013).
45. Matysik, S., Le Roy, C. I., Liebisch, G. & Claus, S. P. Metabolomics of fecal samples: a practical consideration. *Trends Food Sci. Technol.* **57**, 244-255 (2016).
46. Naz, S., Vallejo, M., García, A. & Barbas, C. Method validation strategies involved in non-targeted metabolomics. *J. Chromatogr. A* **1353**, 99–105 (2014).
47. Roelants, M., Hauspie, R. & Hoppenbrouwers, K. References for growth and pubertal development from birth to 21 years in Flanders, Belgium. *Ann. Hum. Biol.* **36**, 680–94 (2009).
48. Cole, T. J. & Lobstein, T. Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. *Pediatr. Obes.* **7**, 284–294 (2012).

Acknowledgements

This work was supported by VLAIO (grant number IM 150740 – A16/OC/0006), BOF GOA (grant number 2017/000102), BOF (grant number 01J07519), FWO Hercules (grant number AUG/17/09), FWO (grant numbers 1S57920N and 1S49020N) and ERC FWO Runner-up (grant number G0G0119N). The Lab of Chemical Analysis research group is part of the Ghent University expertise centre MSsmall.

Authors contributions

V.P., L.V.M., M.D.G., M.D.S., E.D.P. and S.C. wrote the original draft of the manuscript. V.P., L.V.M., E.V.W. and A.P. carried out the experiments. M.D.G. and A.P. performed the data analysis. L.V.M., E.D.P. and S.C. collected the samples. Z.T. and S.C. developed the technique.

L.V., Z.T. and S.C. supervised the project and provided the funding. L.V., M.D.S. and L.V.M. performed the proofreading and correction of the manuscript.

Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Additional information

Supplementary information is available for this paper at xxx.

Reprints and permissions information is available at www.nature.com/reprints.

Correspondence and requests for materials should be addressed to L.V. or S.C.

Related links

Key references using this protocol

Cameron, S. et al. *Anal. Chem.* 91 (21), 13488 (2019):

<https://pubs.acs.org/doi/abs/10.1021/acs.analchem.9b02358>

Wijnant, K. et al. *Anal. Chem.* **92** (7), 5116 (2020):

<https://pubs.acs.org/doi/10.1021/acs.analchem.9b05598>

Van Meulebroek, L. et al. *Talanta* **217**, 121043 (2020):

<https://www.sciencedirect.com/science/article/pii/S0039914020303349>

FIGURES

Fig. 1. | A schematic representation of the LA-REIMS workflow. Technical scheme of the LA-REIMS set-up whereby a laser beam is focused onto a sample, being placed on either an

1250 automated stage equipped to handle 96-well plates or a microscope slide for single samples.
1251 Rapid heating and evaporation takes place and the resulting analyte-containing aerosol is
1252 aspirated towards the mass spectrometer under the instrument's internal vacuum. The
1253 vapour is mixed with a solvent matrix containing lock mass / external standards and collides
1254 with a heated collision surface to form gas-phase ions for analysis. Ions are analysed using a
1255 quadrupole time-of-flight mass spectrometer and the resulting mass spectra are used in
1256 multivariate and machine learning classification models.

- 1257 - **Okay. From this figure, I can see why the standards are referred to as “external”.**
- 1258 - **Why are there two arrows for aerosol transfer?**
- 1259 - **I don't understand the graphic for the flight chamber.**
- 1260 - **To what extent is the multivariate modelling and machine learning specific to this**
- 1261 **type of experiment i.e. specific to LA-REIMS?**

1262
1263

1264 **Fig. 2. | A flowchart of a standard LA-REIMS biofluid analysis experiment.** Summary of
1265 steps involved in the implementation of LA-REIMS for molecular fingerprinting of biofluids,
1266 with time indications per step.

- 1267 - This is great
- 1268 - Consider mentioning the other boxes in the flow diagram?
- 1269 - Move the mention of Box 1 to the blue box on the right?

1270

1271 **Fig. 3. | Typical burns for LA-REIMS analysis.** LA-REIMS burns as acquired for a stool sample
1272 in negative (a) and positive (b) ionization mode, with an MS scan time of 0.3 s per scan and
1273 (automated) laser ablation time of 3 s.x

From this it seems that the instrument is continuously scanning. I am intrigued about the baseline. I assume that this should be a constant that is made up of the solution that may or may not contain external standards.

Fig. 4. | Close-up of the motorized automated sampling area and its connection to the REIMS source: (a) Configuration of the motorised stage, with the laser beam focused on the surface of the stage and the sample tube positioned above the laser focus point. (b) Picture of the connection of the sample tube through the stainless-steel T-shaped connector piece with the solvent line and the inlet of the REIMS source.

Fig. 5. | Typical mass spectra as obtained by LA-REIMS analysis of human biofluids. Acquired spectra for saliva (a, positive ionization; b, negative ionization), plasma (c, positive; d, negative), urine (e, positive, f, negative), stool (g, positive; h, negative), milk (i, positive; j, negative), and sputum (k, positive; l, negative), as obtained by a Waters Xevo G2-XS qToF instrument. Adaptation from Van Meulebroek *et al.* (2020)¹⁰ and Wijnant *et al.* (2020)¹¹.

- This is good as a quick “difference between sample types”.
- I wonder whether it would be good to have an annotated version showing some detail – perhaps truncating at the first or second notch on the y axes, and highlighting main metabolites that you would expect to see in the various sample types.

Fig. 6. | Typical m/z profiles as obtained by LA-REIMS analysis of human biofluids. Number of features that were measured per m/z -class upon LA-REIMS analysis of saliva, plasma, urine, feces, milk, and sputum, in positive (a) and negative (b) ionization mode. For each

matrix type, a single list of m/z -features was acquired, based on the processing of ten rawfiles (single burns), as obtained from ten different samples (i.e. individuals).

- I wonder if this is the best way of showing this information. I think that the profile for each sample type might be more informative. i.e. the items on the x axis are the sample types, and the different coloured bars are different m/z classes. The problem with this current figure is that it is difficult to see that sputum has a different profile to urine. (for example)

Fig. 7. | Multivariate modelling of pathophysiological state based on LA-REIMS

fingerprints. PCA-X (a) and OPLS-DA (b) score plot upon LA-REIMS fingerprinting of feces to discriminate adults according to glycaemic state, *i.e.* type 2 diabetes (dark grey) (n = 36) and euglycemia (light grey) (n = 36). PCA-X (c) and OPLS-DA (d) score plot upon LA-REIMS fingerprinting of saliva to discriminate adolescents according to weight status, *i.e.* healthy weight (dark grey) (n = 35) and overweight/obesity (light grey) (n = 35). Adaptation from Van Meulebroek *et al.* (2020)¹⁰ and Wijnant *et al.* (2020)¹¹.

a **b**